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Chapter 1 
INTRODUCTION AND OUTLINE OF THE STUDY 
INTRODUCTION 
This thesis reports the results of a clinical trial in patients with 
ankylosing spondylitis. Before going into the outlines of the study 
aspects of the disease are discussed, especially the diagnostic crite-
ria, its early diagnosis, the assessment of disease activity, and also 
the motivation and purpose of drug trials in ankylosing spondylitis. 
Diagnostic criteria and early diagnosis 
In ankylosing spondylitis symptoms and signs are not pathognomic, and 
' in the early phases the diagnosis can be difficult (1,2). Therefore, 
defined diagnostic criteria are necessary for clinical use and also for 
the selection of comparable groups, when groups of patients with anky-
losing spondylitis are studied. Initially in 1961 the Rome criteria (3) 
were proposed (table I), and evaluation led in 1966 to modifications 
resulting in the New York criteria (4), in which a sacroiliitis was 
considered a condition sine qua non (table II). 
Table I. ROME CRITERIA FOR ANKYLOSING SPONDYLITIS (3) 
1. Low back pain and stiffness of over 3 months' duration which is not 
relieved by rest. 
2. Pain and stiffness in the thoracic region. 
3. Limited motion in the lumbar spine. 
li. Limited chest expansion 
5. A history or evidence of iritis or its sequelae. 
6. X-ray showing bilateral sacroiliac changes characteristic of ankylo-
sing spondylitis. 
The diagnosis is definite if four of the five clinical criteria are 
fulfilled or if criterion no. 6 and one other criterion are fulfilled 
However, these criteria were not ideal to promote an early diagnosis in 
the individual patient (5,6). Calm et al (7) suggested the possibility 
to diffferentiate between back-pain of an inflammatory nature and that 
of a mechanical or non-specific type based on the clinical history 
(table III). By comparing patients with a sacroiliitis without syndes-
mophytes and patients with a radiographic confirmed lumbar disc disease 
Sadowska et al (8) found a complex of clinical features suggesting the 
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presence of an early ankylosing spondylitis (table IV). The presence of 
the HLA-B27 antigen was found to be associated with ankylosing 
spondylitis (9,10,11), but could neither be used as a screening test 
nor confirm the diagnosis (12,13,14). 
Table II. NEW YORK CRITERIA FOR ANKYLOSING SPONDYLITIS (4) 
Clinical criteria 
1. Limitation of motion of the lumbar spine in all three planes -
anterior and lateral flexion and extension. 
2. A history of or the presence of pain at the dorso-lumbal junction or 
in the lumbar spine. 
3. Limitation of chest expansion to 2.5 cm or less. 
Grading of radiographs of the sacroiliac joints 
0. Normal. 
1. Suspicious changes. 
2. Minimal abnormality - small localized areas with erosion or 
sclerosis, without alteration in the joint width. 
3. Unequivocal abnormality - moderate or advanced sacroiliitis with one 
or more of: erosions, evidence of sclerosis, widening, narrowing, or 
partial ankylosis. 
4. Severe abnormality - total ankylosis. 
A definite AS is present if there is grade 3-4 bilateral sacroiliitis 
with at least one clinical criterion, or if there is grade 3-4 unila-
teral or grade 2 bilateral sacroiliitis with criterion 1 or with both 
clinical criteria 2 and 3. 
A probable AS is present if there is grade 3-4 bilateral sacroiliitis 
without any clinical criteria. 
Table III. CLINICAL HISTORY AS A SCREENING TEST FOR 
ANKYLOSING SPONDYLITIS (7) 
At what age did you discover your back discomfort9 
•Age of onset less than 40 years. 
Did the problem begin suddenly or slowly7 
Insidious onset of pain. 
Has the discomfort ever gone on for three months or more7 
Duration of at least three months. 
Has the back been stiff, especially in the morning9 
Association with morning stiffness. 
Has the discomfort been improved by rest or exercise9 
Improvement with exercise and aggravation upon rest. 
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Table IV. CLINICAL FEATURES INDICATING EARLY ANKYLOSING 
SPONDYLITIS (8) 
1. History data: low back morning stiffness 
swelling of knee joint 
girdle chest pains 
2. Clinical examination: chest expansion decreased below 5 cm 
swelling of lower extremity joints 
positive Menell's sign 
3. Laboratory investigations: raised ESR value 
raised seromucoid level 
HLA B27 antigen 
Assessment of disease activity 
The course of ankylosing spondylitis is characterized by spontaneous 
remissions and exacerbations (15,16,17), and the observed changes in 
disease activity during drug treatment may partly reflect naturally 
occurring relapses and remissions. 
Spinal pain and stiffness are the most frequent complaints of the pa-
tients, especially troublesome at night and in the morning. In a chro-
nic disorder, like ankylosing spondylitis, patients become more or less 
accustomed to their pain and stiffness, depending on duration and se-
venty of the disease. This may cause problems in evaluating seventy. 
The physical examination reveals a diminution of both chest expansion 
and spinal mobility, which represent important and early clinical fea-
tures (18). However, a decreased mobility does not need to be accompa-
nied with complaints, as in case of inactive disease with residual im-
pairment. Several clinical tests, to stress the sacroiliac joints, lack 
specificity due to the difficult accessibility and small mobility of 
the joints (19,20,21). Therefore, the diagnosis sacroilntis depends 
largely upon radiological features. It was observed by relating the 
clinical picture with the extent of abnormal radiological features, 
that some patients may proceed rapidly at an early stage to the classi-
cal spinal rigidity with syndesmophytes and flexion deformity, while in 
others the disease progresses very slowly with even after many years 
only minor clinical and radiological abnormalities (18,22). So radiolo-
gical abnormalities reflect merely disease activity in the past. 
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The ESR is usually moderately raised in most patients with ankylosing 
spondylitis, but according to most authors this parameter correlates 
poorly with clinical disease activity assessments, especialy in the ab-
sence of peripheral arthritis (23,24,25,26). Various measurements of 
the acute phase response, like CRP, tend to be higher in patients with 
clinically active disease, but less marked when only a pelvospondylitis 
is present (24,26,27,28). Serum immunoglobulins have also been shown to 
be elevated in ankylosing spondylitis (29,30), the most dominant being 
a raised serum IgA (26,27,31). A relationship between a disproportiona-
te increase in IgA levels with disease activity has been suggested 
(26,31). 
Despite the above mentioned limitations, the seventy of pain and 
stiffness and mobility impairment provide useful measurements to assess 
disease activity. However, as a result of therapeutic intervention some 
parameters may improve and others may not be influenced. In practice 
physicians therefore aggregate the obtained information in order to 
come to an overall judgement regarding disease activity. This implicit 
global assessment is difficult to standardize and non-disease related 
factors may play a disturbing role. In an attempt to solve this problem 
several investigators have developed indices combining, in a standard-
ized quantitative way, the separate parameters (32,33,34,35). 
Motivation for doing clinical trials 
The randomized controlled clinical trial has become the widely accepted 
method for evaluating the efficacy and safety of new treatments in 
rheumatic diseases (36,37,38) for two main reasons. Firstly the dis-
eases have a variable expression with spontaneous fluctuations; second-
ly up to now no curative agent for these diseases has been found. More-
over, clinical trials can also be applied to assess the value of cer-
tain efficacy parameters and other, non-drug, aspects of patient ma-
nagement or the disease under study. Unfortunately in rheumatic di-
seases one has to rely on evaluation criteria, which are not entirely 
objective and not easy to quantify. Therefore, once more a double-blind 
approach is necessary. 
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Aim of the study 
The purpose of this study was to investigate the efficacy and safety of 
diflunisal, a salicylic acid derivative, in ankylosing spondylitis by 
using phenylbutazone, a pyrazolon derivative, as a reference drug. The 
48 weeks trial was divided into a double-blind phase of 12 weeks, and 
an open extension period of 36 weeks in which dosage adjustments could 
be made. The open period was performed to get information about the 
optimal dosage range and long-term safety and tolerance. Moreover, this 
clinical trial gave the opportunity to study the value of different 
efficacy parameters. 
GUTLINE OF THE STUDY 
Since its introduction in 1949 phenylbutazone (PBZ) has been widely 
used as an anti-inflammatory drug in ankylosing spondylitis. Upon chro­
nic dosing the oxidative metabolism of this drug becomes more important 
yielding oxypenbutazone (OPBZ) and gamma-hydroxyphenylbutazone (γΟΗΡΒΖ) 
as major metabolites in plasma (39). The development of an appropriate 
method for determination of PBZ and its major metabolites was hampered 
by degradation not only upon storage, but also during the assays (40, 
41). In order to monitor PBZ therapy, and for detailed pharmacokinetic 
studies a modification of the HPLC method in which special care is ta­
ken to avoid degradation during specimen handling was necessary. This 
procedure is described in chapter 2. 
Naproxen has proven to be an effective and well tolerated agent in an­
kylosing spondylitis in a dosage up to 750 mg daily (42,43). PBZ and 
naproxen have a similar pharmacokinetic profile, both show non-linear 
kinetics because of saturable plasma protein binding capacity (44,45). 
Because its haematological side effects large scale volunteers studies 
with PBZ are unethical. Studies in man have shown that plasma levels of 
naproxen rose disproportionately when the dosage was increased above 
500 mg twice daily (45). In contrast with the very long half life time 
of PBZ (70 hours) the half life of naproxen is much shorter (12-15 
hours). According to this half life, and the clinical observation that 
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the painfull stiffness in ankylosing spondylitis is most troublesome at 
night and in the early morning one might expect one appropriate daily 
dose taken in the evening to be as effective as twice daily dosing. Ta-
ken into account the non-linearity pharmacokinetic differences upon two 
dosage regimens of 1000 mg naproxen, 1000 mg once versus 500 mg twice 
daily, are possible, and may result in lower plasma levels in the once 
daily dosing due to an increased excretion. Data on these pharmacokine-
tic differences upon two dosage regimens in healthy volunteers are pre-
sented in chapter 3. 
In clinical practice and trials, disease activity in ankylosing spon-
dylitis is usually judged by the seventy of spinal pain and morning 
stiffness and the degree of mobility impairment, measured by means of 
chest expansion and lumbar flexion. Besides a judgement of the outcome 
of the individual parameters another often applied approach is the 
overall assessment, in which global evaluations concerning activity and 
response are used. A comparison is made with pre-trial conditions or 
with baseline values arising after a drug withdrawal period. Although 
such global assessments are useful as a judgement of the patient's ge-
neral condition they rely primarily on subjective impressions of obser-
vations more and more distant in time, and are subject to a consider-
able variation. Combining clinically relevant disease related parame-
ters in a composite index may overcome these problems in assessing ac-
tivity and efficacy in terms of an integral conclusion (33). Chapter 4 
describes a proposal for such an index of disease activity (IDA) in an-
kylosing spondylitis. 
By decreasing pain and stiffness non-steroidal anti-inflammatory drugs 
(NSAIDs) are up to now the most effective agents in ankylosing spondyl-
itis, and provide the best way to preserve posture and maintain or im-
prove mobility m combination with physical therapy and an active daily 
exercise regimen. 
Salicylic acid and its derivatives have never become drugs of choice 
in ankylosing spondylitis. For some years the new salicylic acid deri-
vative, diflumsal, was introduced with fewer side effects, greater po-
tency and longer duration of action than its parent drug (46). As the 
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value of diflunisal in the treatment of ankylosing spondylitis had 
never been studied, it seemed warranted to study the efficacy and safe-
ty of this NSAID in ankylosing spondylitis by means of a randomized 
controlled clinical trial with phenylbutazone as the reference drug. 
Chapter 5 provides data about this drug trial. 
In ankylosing spondylitis the inflammatory process is gradually exten-
ded over the chest, resulting in a reduction of the chest expansion and 
in a restrictive lung function impairment in a considerable number of 
patients (47). Diaphragmatic mobility remains normal and compensates to 
a certain extent (48). Renzetti et al (49) have suggested that the vi-
tal capacity may be used as an objective criterion for evaluation of 
the seventy of the thoracic impairment, and perhaps as an indication 
of its progression or response to therapy. Chapter 6 describes the in-
fluence of disease activity and treatment with NSAIDs on the ventilato-
ry function, and comments on vital capacity as a possible parameter. 
The unifying concept of the seronegative Spondarthritis has led to the 
search of common etiological factors in these disease entities (50). 
Since it was known that a reactive arthritis can be precipitated by an 
enteric infection (51) the attention was drawn on the gastrointestinal 
tract as a possible focus of antigenic stimulus causing ankylosing 
spondylitis (52). Raised serum levels of IgA in patients with active 
ankylosing spondylitis would be compatible with this concept, since hu-
moral responses in the gut are mainly of the IgA type (28,31). Another 
reason to focus on IgA was the absence of a specific laboratory mea-
surement to assess disease activity in ankylosing spondylitis. In order 
to prevent the occurrence of a flexion deformity it is important to 
know if an ongoing spondylitis is present. Up to now no objective labo-
ratory parameter was found, which could be used as a guide indicating 
activity spondylitis and progressive ankylosis. These considerations 
have prompted us to investigate in a prospective way the relation be-
tween serum IgA and conventional clinical parameters assessing disease 
activity; the findings are described in chapter 7. 
The final chapter gives a summary and conclusion of the findings. 
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Chapter 2 
SPECIMEN HANDLING IN A HPLC DETERMINATION OF PHENYLBUTAZONE AND ITS 
MAJOR METABOLITES IN PLASMA AVOIDING DEGRADATION OF THE COMPOUNDS 
MJAM Franssen, Y Tan, I Freij, CAM van Ginneken, FWJ Gribnau 
submitted for publication 
SUMMARY 
A problem usually not taken into account when a quantitative HPLC me-
thod for phenylbutazone is developed is the degradation of this drug 
and its metabolites not only upon storage, but also on extraction under 
acidic conditions, especially when the temperature is raised. Moreover 
the degradation products in the chromatograms may interfere with the 
determination of gammahydroxyphenylbutazone. In our newly developed 
HPLC method, using feprazone as an internal standard, extreme care is 
taken to avoid degradation of the compounds during the extraction pro-
cedure. In view of the present results it is concluded that previously 
published data on phenylbutazone, oxyphenbutazone and gammahydroxyphe-
nylbutazone levels should be considered with reserve. 
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INTRODUCTION 
Since its introduction in 1949 phenylbutazone has been widely used as 
an anti-inflammatory drug and has proved to be an effective analgesic. 
Lastly, because of haematologic side effects of phenylbutazone (Inham, 
1977), its use is restricted to ankylosing spondylitis. Soon after its 
introduction Burns et al (1953) described a spectrophotometnc method 
for the determination of phenylbutazone in biological fluids. They also 
demonstrated oxydative metabolic pathways yielding oxyphenbutazone and 
gammahydroxyphenylbutazone (Burns et al, 1955). Since then several 
other methods for the determination of phenylbutazone and its metaboli-
tes have been described, including spectrophotometnc methods (Wallace, 
1968), gas liquid chromatographic methods (Perego et al, 1971; 
McGilveray et al, 1974; Bruce et al, 1974; Midha et al, 1974; Sioufi et 
al, 1978; Budd, 1982) and high performance liquid chromatographic me-
thods (Pound et al, 1974; Pound et al, 1975; Alvinene et al, 1980; 
Aarons et al, 1980; Marunaka et al, 1980). Each of these methods has 
its disadvantages. Some of these methods are only suitable for the de-
termination of phenylbutazone. In general the problems are lack of sen-
sitivity or selectivity and especially the fact, usually overlooked, 
that phenylbutazone and its metabolites can degrade to a substantial 
degree (Belleward et al, 1972; Awang et al, 1973; Matsui et al, 1980; 
Fahre et al, 1982). This degradation occurs not only upon storage, but 
also on extraction under acidic conditions, especially when the temper-
ature is raised. Therefore the handling of the biological samples dur-
ing the extraction procedure is critical. 
The essential point of our newly developed method for measuring phenyl-
butazone and its oxidative metabolites is that extreme care has been 
taken to avoid degradation during sample preparation. In this procedure 
0.345 M citrate buffer (pH 2.0) is used to acidify the plasma sample, 
instead of the common 1-5 N HCl and the extraction tubes are centnfug-
ed at +4 0C. Feprazone is used as an internal standard. The method was 
successfully applied in human studies. 
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MATERIALS AND METHODS 
Reagents and drug 
Methanol, citric acid, sodium hydroxide, hydrochloric acid, diethyl 
ether, n-hexane, sodium hydrogen carbonate, tris(hydroxymethyl)-
aminomethane and 1-butanol were obtained from Merck (Darmstadt, ERG). 
Diethyl ether was distilled shortly before use. Tetrabutylammonium hy­
drogen sulfate was obtained from Janssen Chimica (Beerse, Belgium). All 
reagents were of analytical grade quality. Commercial available dosage 
forms of phenylbutazone (Butazolidin Alka") and oxyphenbutazone 
(Tanderil") were used. Gamma hydroxy phenylbutazone and feprazone 
were kindly supplied by Ciba-Geigy (Arnhem, The Netherlands) and C.H. 
Boehnnger Sohn Ingelheim am Rhein (ERG) respectively. 
Biological fluids 
Human blood plasma stored at -20 0 C was obtained from the local blood 
bank. Erom one male individual blood was collected in heparmized con-
tainprs and centnfuged to separate the plasma after a single oral dose 
administration of two 100 mg Butazolidin Alka" tablets. From another 
male individual plasma was obtained in the same manner after a single 
oral dose administration of two 100 mg Tanderil" tablets, further­
more, plasma samples were collected from 11 patients with ankylosing 
spondylitis during a trial comparing diflumsal with phenylbutazone. 
All patients used phenylbutazone for at least three months. 
Apparatus and chromatographic conditions 
A Hewlett-Packard HP 1084 В liquid Chromatograph equipped with an auto­
matic sampling system was used. The compounds eluted were measured with 
a variable wavelength detector (Spectroflow 773, Kratos, Analytical 
Instruments, New Jersey, USA). The detection wavelength was 248 nm. The 
stainless steel column (15 cm χ 4.6 mm I.D.) was packed with Li-
Chrosorb RP-18, mean particle size 5 μπι (Merck). The oven temperature 
was 35 0 С and the injection volume was 10 μΐ. 
The mobile phase was a mixture of methanol, 1-butanol and twice dis­
tilled water (37:6:57) containing 0.0102 M tetrabutylammonium hydrogen 
sulphate and 0.0098 M tris(hydroxymethyl)-aminomethane (pH 4.0). This 
26 
was delivered at a rate of 1.0 ml/min, producing a pressure of 218 
bar. The mobile phase was prepared as follows: 3.74 g of tetrabutyl-
ammonium hydrogen sulphate (mol.wt.= 339.54) were dissolved in 314 ml 
twice-distilled water and 1.33 g tris(hydroxymethyl)-aminomethane 
(mol.wt. = 121.14) were dissolved in 314 ml twice-distilled water. The 
latter solution was added to the tetrabutylammonium hydrogen sulphate 
solution until pH 4.0 was attained (301 ml were required). Next, the 
mixture was filtered through a 0.45 μπι Millipore filter and 370 ml me­
thanol and 60 ml 1-butanol were subsequently added to 570 ml of the 
filtered mixture. 
Procedure 
Into an extraction tube, which already contained 200 μΐ methanol (con­
taining phenylbutazone, oxyphenbutazone and gammahydroxy phenylbutazone 
when making calibration curves) 100 μΐ of internal standard (10 or 50 
mg feprazone per 100 ml methanol in single dose or steady state studies 
respectively) were pipetted. Aliquots of 0.5 ml of plasma, 0.7 ml of 
0.345 M citrate buffer pH 2.0 and 5 ml of the diethyl ether-n-hexane 
(50:50) were successively pipetted into the extraction tube. 
The extraction tube was closed with a polytetrafluoro-ethylene (PTFE) 
screw-cap. After whirl mixing for 2 seconds the tubes were tumbled me­
chanically for 30 minutes at 12 r.p.m. at room temperature, followed by 
centnfugation at 13G0 g for 30 minutes at +4 0C (Mimfuge 2, Heraeus-
Chnst GmbH, Osterode am Harz, FRG) . The organic layer was pipetted in­
to another extraction tube containing 100 mg sodium hydrogen carbon­
ate. The tube was closed with a screw-cap and tumbled by hand for 12 
seconds. The screw-cap was opened to let the CO2 formed escape (12-15 
m m ) , followed by gentle whirl mixing for 2 seconds. After centnfuga­
tion at 1300 g for 5 minutes at +4 0 C , the organic layer was transfer­
red to a test tube and evaporated to dryness with a gentle stream of 
nitrogen at 25 0 C . The residue was dissolved in 1.0 ml of methanol. 
After addition of 0.2 ml of twice distilled water, 10 μΐ of this mix­
ture were injected into the column. 
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RESULTS 
Figure 1 shows typical chromatograms for blank plasma and for plasma 
containing 10.0 цд/ті gammahydroxyphenylbutazone, 10.0 μg/ml oxyphenbu-
tazone, 20.0 μg/ml phenylbutazone and 20.0 цд/ті of the internal stan­
dard feprazone. 
The retention times of gammahydroxyphenylbutazone, oxyphenbutazone, 
phenylbutazone and feprazone were about 5.72, 6.86, 16.94 and 20.10 mi­
nutes respectively. Most of the endogenous peaks had a retention time 
shorter than 4 minutes, one endogenous peak between the peaks of oxy­
phenbutazone and phenylbutazone had a retention time of 11.0 minutes. 
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Figure 1. Chromatograms obtained from blank plasma (I) and plasma con­
taining (A) 10.0 μg/ml gammahydroxyphenylbutazone, 
(B) 10.0 μg/ml oxyphenbutazone, 
(C) 20.0 μg/ml phenylbutazone, and 
(0) 20.0 μg/ml feprazone (II). 
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Figure 2 shows chromatograms for plasma containing 20 μg/ml phenylbuta­
zone and 10 μg/ml oxyphenbutazone using 0.5 ml IN HCl instead of 0.7 ml 
0.345 M citrate buffer pH 2.0. A considerable degradation occurred 
during the extraction procedure resulting in decomposition products 
with a retention time of 13.91 minutes for phenylbutazone, and 5.57 
resp. 6.00 minutes for oxyphenbutazone, the latter two peaks coincide 
with the peak of gammahydroxyphenylbutazone (Figure 1). 
0.0008 AU 
ν~Λ 
u. 
_ / w 
Ο 8 16 24 
Time (min) 
О 
JO.OOOSAU 
В 
8 16 24 
Time (min) 
Figure 2. Chromatograms obtained from plasma containing (B) 10 μg/ml 
oxyphenbutazone and (C) 20 μg/ml phenylbutazone using 1 N HCl 
with the occurrence of (E) degradation products 
Calculation 
The concentrations of phenylbutazone and its two major metabolites 
oxyphenbutazone and gammahydroxyphenylbutazone in a plasma sample were 
determined by comparing the peak height ratio (phenylbutazone or its 
metabolites/internal standard) with a standard curve of peak height 
ratio versus concentrations of phenylbutazone or its metabolites. 
Whenever a sample was measured, standard curves were generated by 
adding different amounts of phenylbutazone and its metabolites to blank 
plasma and analyzing them by the method already described. As is shown 
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by the regression equations in table I a linear relationship was found 
between the peak height ratio of phenylbutazone and its metabolites to 
feprazone (Y) and the plasma concentrations of phenylbutazone and its 
metabolites (X). 
Table I. REGRESSION EQUATIONS OF THE CALIBRATION CURVES IN TWO CONCEN­
TRATION RANGES WITH INTERNAL STANDARD CONCENTRATION 
(FEPRAZONE) OF 11 (*) OR 110 (**) μg/ml 
Compound measured Concentration Regression Correlation 
Range μς/ιηΐ equation coefficient 
phenylbutazone* 0.78 - 15.68 Y= 0.1230X-0.0173 0.999Θ 
oxyphenbutazone* 0.56 - 4.48 Y= 0.2147X-0.0029 0.9997 
gammahydroxyphenyl- 0.55 - 4.40 Y =0.2289X-0.0265 0.9991 
butazone* 
phenylbutazone** 
oxyphenbutazone** 
gammahydroxyphenyl 
butazone** 
Recovery 
Overall recovery was determined by comparing the peak heights of phe­
nylbutazone, oxyphenbutazone, gammahydroxyphenylbutazone and feprazone 
after injection of standard solutions with peak heights obtained after 
injection of extracted standard solutions (table II). 
Recoveries measured were high except for gammahydroxyphenylbutazone. 
All recoveries were very reproducible. 
Sensitivity and precision 
The detection limit with the analysis described was 0.1 μg/ml for phe­
nylbutazone, 0.25 цд/ті for both oxyphenbutazone and gammahydroxyphe­
nylbutazone. The within-day precision is given in tables III, IV and 
V. The between-day precision was in the same order of magnitude as the 
within-day precision. 
Amounts of oxidised metabolites after single and repeated dosing in man 
After a single oral dose of 200 mg of phenylbutazone (figure 3) or 200 
7.84 - 156.8 Y= 0.01229X-0.01951 0.9997 
1.12 - 22.4 Y= 0.02153X+0.000409 0.9998 
2.2 - 44.0 Y= 0.01952X-0.0116 0.9998 
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Table II. RECOVERY OF PHENYLBUTAZONE, OXYPHENBUTAZONE, GAMMAHYDROXYPHE­
NYLBUTAZONE AND FEPRAZONE IN PLASMA (all determinations were 
made in six-fold) 
Compound 
phenylbutazone 
oxyphenbutazone 
gammahydroxyphenyl­
butazone 
feprazone 
Co ncentration 
μg/ml 
11.2 
156.8 
4.4Θ 
22.4 
4.4 
44.0 
11.0 
110.0 
Me an 
Recovei 
95 
92 
86 
83 
66 
65 
92 
94 
•y % 
Coëfficiënt 
Variation % 
2.0 
1.6 
4.4 
2.0 
4.4 
4.6 
2.2 
1.4 
Table III. ANALYSIS OF SPIKED PHENYLBUTAZONE PLASMA SAMPLES 
(all determinations were made in six-fold) 
Sample 
1 
2 
3 
4 
5 
6 
7 
8 
9 
Concentration 
μg/ml 
0.94 
1.86 
3.92 
7.70 
15.75 
19.35 
39.78 
76.89 
156.41 
Coëfficiënt of 
Variation % 
2.7 
2.7 
0.8 
1.3 
0.3 
1.1 
0.7 
0.8 
0.2 
mg of oxyphenbutazone no gammahydroxyphenylbutazone was found. During a 
longterm treatment with 200 mg phenylbutazone twice daily in patients 
with ankylosing spondylitis we found a steady state plasma concentra-
tion of 87.2 + 16.5 μg/ml of phenylbutazone, whereas the plasma concen­
tration of oxyphenbutazone and gammahydroxyphenylbutazone were 11.1 + 
2.9 and 13.1 + 7.2 цд/ті respectively (means +_ SD, n=7). 
These figures, expressed as percentage of the total amount of compounds 
measured (i.e. the sum of the molar concentrations of phenylbutazone, 
oxyphenbutazone and gammahydroxyphenylbutazone in the individuals; this 
total = 1002Í) are: phenylbutazone 78 _+ 5Sá, oxyphenbutazone 12 + 5% and 
gammahydroxyphenylbutazone 10 + b% respectively. 
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Table IV. ANALYSIS GF SPIKED OXYPHENBUTAZONE PLASMA SAMPLES 
(all determinations were made in six-fold) 
Sample 
1 
2 
3 
й 
5 
6 
7 
θ 
Co ncentrat 
μς/πιΐ 
0.60 
1.14 
2.14 
3.36 
4.52 
5.66 
11.08 
22.45 
i o n C o e f f i c i e n t 
V a r i a t i o n % 
10.4 
4 . 8 
2.3 
3.3 
1.8 
3.4 
2.1 
0 . 4 
Table V. ANALYSIS OF SPIKED GAMMAHYDROXYPHENYLBUTAZONE PLASMA SAMPLES 
(all determinations were made in six-fold) 
Samples 
1 
2 
3 
4 
5 
6 
7 
8 
Concentrât 
цд/піі 
0.61 
1.12 
2.11 
3.22 
4.49 
5.37 
11.46 
21.06 
i o n C o e f f i c i e n t o f 
Var ia t ion % 
8 . 4 
3.5 
2.8 
4 . 0 
1.9 
4.5 
3.3 
3.2 
DISCUSSION 
With most of the published methods HCl (1-5 Ν) was used to acidify the 
samples. Pound et al (1974) pointed out that traces of aqueous acid, 
which might have been carried over in some of the tubes caused 
degradation of phenylbutazone. 
Even though Perego et al (1971) used η-heptane to extract their samples 
after acidification with 1 N HCl, they found it necessary to dry the 
organic layer over N3250^. When benzene, chloroform or ether is used as 
extraction solution, it is quite sure that more aqueous acid will be 
carried over which can cause degradation of phenylbutazone whenever no 
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Figure 3. Plasma concentrations of phenylbutazone and oxyphenbutazone 
after a single oral intake of 200 mg phenylbutazone. 
precautions are taken. It was our experience too that degradation of 
phenylbutazone and oxyphenbutazone took place when we used 1 N HCl to 
acidify our samples. Besides, in the chromatogram the peak of the de­
gradation product of oxyphenbutazone coincide with the peak of gammahy-
droxyphenylbutazone. The degradation took place more quickly when the 
temperature of the extraction tubes rose during centnfugation. We 
found a degradation of more than 50%. 
To overcome these problems we used 0.345 M citrate buffer (pH 2.0) in­
stead of 1 N HCl. Furthermore, the extraction tubes were centnfuged at 
+4°С instead of at room temperature with a centrifuge with cooling. We 
found a temperature rise above 250C when the extraction tubes were cen­
tnfuged at room temperature. Before evaporation to dryness with nitro­
gen, traces of acid were neutralized with solid NaHCOj. 
As mentioned, upon a single dose of 200 mg we did not find any gammahy-
droxyphenylbutazone; Aarbakke et al (1977) and Dieterle et al (1976) 
phenylbutazone 
oxyphenbutazone 
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upon a single oral dose of 600 or 400 mg respectively found up to 2.С 
resp. 0.8 μg/ml in plasma possibly due to degradation of oxyphenbuta­
zone in the procedures they used. Regarding the steady state concentra­
tion in this context it might be of relevance that we found a percent­
age of 10 + 5 gammahydroxyphenylbutazone at steady state (n=11) anc 
Aarbakke et al (1977) 13 +^  5% (n=6, this percentage calculated fron 
their data). 
Our method is a rapid and sensitive determination to measure phenylbu­
tazone and its major oxidised metabolites oxyphenbutazone and gammahy­
droxyphenylbutazone in plasma with an extraction procedure that pre­
vents degradation of the compounds and which can easily be used ir 
pharmacokinetic studies. 
In view of the present results it is obvious that previously publishec 
data on phenylbutazone, oxyphenbutazone and gammahydroxyphenylbutazone 
levels during treatment with either Butazolidine" and Tandenl'' 
should be considered with reserve as phenylbutazone and/or oxyphenbuta­
zone levels may be under-estimated and gammahydroxyphenylbutazone 
levels probably are over-estimated. 
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SUMMARY 
The pharmacokinetic differences between two dosage regimens of naproxen 
(1000 mg once daily vs 500 mg twice daily) were studied at steady state 
in seven healthy male volunteers. The twice daily regimen resulted in 
statistically significant higher trough serum levels, larger AUCg
+
24; 
also the time span with a concentration over 50 μg/ml was longer. The 
urinary excretion of naproxen metabolites was slightly greater upon 
once daily dosing. The о
е х
£
Г а
п and, to a lesser extent the total 
body clearance, were larger upon the once daily regimen with a longer 
t1/2p as a consequence. As yet one can only speculate about the 
therapeutic implications of these findings. 
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INTRODUCTION 
The NSAID naproxen is widely used in the therapy of several rheumatic 
diseases. Since the late seventies higher doses of the drug are given 
than the originally recommended 500 or 750 mg (Hazleman et al 1979, 
Luftschein et al 1979, Mowat et al 1984, Thompson et al 1979). The drug 
is usually administered twice daily, but nowadays clinicians tend to 
conclude that a once daily regimen is effective as well, regardless of 
the half-life of the drug. A high dose at night is recommended, espe-
cially when night pain and morning stiffness are dominant symptoms. 
Naproxen (Brogden et al 1979, Runkel et al 1973, 1974) is highly pro-
tein bound, and therefore has a small volume of distribution of about 
0.1 1/kg. Its plasma half-life in man is 12-15 hours. Earlier experi-
ments on naproxen have shown that steady state concentrations of the 
drug upon repeated twice daily dosing are reached after approximately 
three days, whatever dose was used. Urinary excretion of naproxen and 
metabolites turned out to increase parabolically with increasing plasma 
concentration, due to the fact that binding to plasma proteins, which 
is most pronounced at low plasma concentration, effectively inhibits 
the renal excretion of the compounds (Runkel et al 1973, 1974). As 
might be anticipated, the area under the plasma concentration vs time 
curve increases only much less than proportional with increasing dose. 
For this reason it was concluded that increasing the dose above 500 mg 
twice daily did not make sense, as no appreciably higher plasma concen-
trations would be reached, since the drug is more intensively cleared 
at higher concentrations. For the same reason one might expect pharma-
cokinetic differences upon two dosage regimens of 1000 mg naproxen 
daily, 1000 mg once daily versus 500 mg twice daily. We studied the 
pharmacokinetics of naproxen at steady state in healthy volunteers, 
treated with either regimen for 4 days. 
METHODS 
Table I lists details of the volunteers. They were all male. They had 
not been taking any drugs during at least one month preceding the stu-
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Table I. INDIVIDUAL CHARACTERISTICS 
Volunteer 
1 
2 
3 
4 
5 
6 
7 
mean 
SD 
Age 
(yrs) 
28 
19 
24 
22 
22 
24 
22 
23.0 
2.8 
Weight 
(kg) 
57.5 
87.1 
79.В 
71.5 
77.7 
74.0 
65.4 
73.3 
9.7 
Height 
(cm) 
164 
190 
183 
177 
189 
186 
179 
181 
9 
Serum 
Creatinine 
(μπιοΐ/ΐ) 
65 
76 
100 
79 
78 
84 
76 
89 
11 
Serum 
Albumin 
(g/1) 
46 
50 
49 
54 
53 
52 
44 
50 
4 
dy. No drug intake other than the required dosage of naproxen was al­
lowed during the study. Between the two dosage regimens a wash-out pe­
riod of one week was kept. Only volunteers without a history of peptic 
ulcer or gastro-intestinal disease in the past and without hypersensi­
tivity or other severe reactions to NSAID were allowed to enter the 
study. They all gave their informed consent. A health/disease history 
was taken, and a physical and laboratory examination was made. Naproxen 
was supplied as commercially available tablets (Naprosyne^, Sarva-
Syntex, The Netherlands) containing 250 mg of the active compound. Fi­
gure 1 shows the design of the study. All volunteers were treated with 
the once and the twice daily dosage regimen. Naproxen was administered 
either once daily at 8.30 pm or twice daily at 8.30 am and 8.30 pm. The 
morning dose of the drug was taken after an overnight fast with a stan­
dard breakfast. On day IV blood samples were taken for serum naproxen 
measurement, at t = 0; 0.5; 1.5; 3.5; 13 hrs upon the 1000 mg once 
daily, and t =0; 0.5; 1.5; 4.5; 8.5; 12 hrs upon the 500 mg b.i.d. re­
gimen respectively. In the treatment group on 1000 mg once daily on day 
V no 24 hrs plasma sample was taken, because of the very stable predose 
level in this group in the preceding day IV vs day III. The areas under 
the serum concentration time curves were calculated according to the 
trapezoid rule, applied over steady state periods of 24 or 12 hours in 
the once and twice daily regimen respectively. The total body clearance 
was calculated using this AUC and the dosage. The CQ, in the steady 
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Design of the study — 
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Figure 1. Design of the study 
state situation, was estimated by extrapolating the exponential phase 
(using the last three measured time points on the two respective regi­
mens) of the serum concentration time curve of each individual, in a 
semi log plot, to time zero. From CQ the trough serum concentration 
was substracted, giving "Cg extrapolated" (c0 extrap). The apparent 
volume of distribution was calculated as dose divided by Cg extrap· 
Also for each individual at both dose levels the elimination half-life 
at steady state was derived (again from the last three measured concen­
trations upon the two respective regimens). It was assumed that the 
bioavailability of naproxen was 100%. 
All variable data are given as mean with SD. The paired Student's t 
test was used for evaluating possible statistical significance. 
Naproxen analysis was carried out according to Van Loenhout et al 
(19Θ2). For determination of glucuromdes of naproxen and/or desmethyl-
naproxen in urine, ß-glucuromdase (VII; Sigma St. Louis MO, USA) was 
used; to 0.25 ml of urine was added 0.25 ml of 0.2 M phoshate buffer 
(pH 6.8) containing 500 units of ß-glucuronidase; the mixture was incu-
bated for 24 hours at 37°С 
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Abbreviations 
^trough5 serum naproxen concentration just before the next 
dose 
AUCg-»^: area under the serum concentration versus time curve 
over 24 hours ^g/ml/hr) 
tç>5Q: time span with a serum concentration >50 цд/ті 
ALJCg-
>
.24-c>50: paft of the area under the serum concentration 
versus time curve over 24 hours with concentrations 
over 50 μg/ml, the area under this concentration not 
inclusive (pq/ml/hr) 
t1/2R: elimination half-life time (hr) 
^Dextrap! extrapolated apparent volume of distribution (1) 
Cltot: total body clearance (ml/min) 
UEQ^24: 24 hours excretion of naproxen metabolites 
RESULTS 
Irrespective of the dosage regimen stable Ct
r0Uqh values are reached 
after 48 hours. As illustrated in figure 2, pre-dose serum concentra­
tions on once daily dosing are significantly lower than those upon 
twice daily dosing. The AUCo>2413 significantly greater upon the 
twice daily regimen than with the once daily dosage; also the time span 
of serum concentrations over 50 μg/ml is longer when the drug is admi­
nistered twice daily. The difference of AUCQ
>
24· O50 between the two 
regimens does not reach the level of statistical significance. The in­
dividual values of ()
ех
^
га
р, t1/2p, and Cltot a r e given in figure 
3; [)
ех
(
:га
р is greater, t1/2a is longer, and Cl^ot l s greater 
upon once daily dosing. The total urinary excretion of native, 
unglucuromdated naproxen at steady state is maximally 0.1 mmol/24 
hours for either regimen, upon the dose of 4.3 mmol daily. The urinay 
excretion of the naproxen metabolites (UE[)
>
24; naproxen glucuronide, 
desmethyl naproxen, and desmethyl naproxen-glucuronide) is much 
greater, approximately 60% of the dosage. Upon once daily dosing the 
UEQ
>
24 exceeds the UEQ
>
24 when the drug is given twice daily. The 
results are summarized in table II. 
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^naproxen (j-Lg/ni 
140 
96 120 
T ime (hours) 
Figure 2. Serum naproxen concentrations fo l lowing adminis t rat ion of a 
dose of 1000 mg once da i ly ( ) or 500 mg twice da i ly ( ) 
V D e x t r a p . < l > % ( h r S ) % ^ ^ ^ 
12 15-
-10 13 
8 11 
f 6 9 
!ß 
И5 15-1 
13 13 
11 11 
9 9 
4 J L 4 7 J L у 7 J 1-7 
1 dd. bid. 1 d.d. b.i.d. 1 d.d. b.i.d. 
Figure 3. Values of V D e xt r ap, t1/2ß and Cltot upon once versus 
twice daily dosing in each subject 
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Table II. KINETIC PARAMETERS OF NAPROXEN UPON ONCE (1000 mg) OR TWICE 
(500 mg b.i.d.) DAILY DOSING 
NAPROXEN 
Ctrough 
AUC0+24 
t o s o 
AUCQ^24; O50 
t1/2p 
^Dextrap 
" t o t 
UE0>24 
(μg/ml) 
(цд/тІ/Ьг) 
(hr) 
(цд/тІ/Ьг) 
(hr) 
(1) 
(mi/min) 
(mmol/24 hr) 
1000 mg 
1 d . d . 
34 + 7 
1650 + 230 
16.3 + 4.0 
500 + 160 
12.3 + 1.7 
10.2 + 1.5 
10.3 + 1.7 
2.5 + 0.2 
500 mg 
b . i . d . 
50 + 8 
17 0 + 2 1 0 
20.0 + 4.5 
590 + 190 
9.5 + 0.8 
7.7 + 0.9 
9.5 + 1.2 
2.2 + 0.4 
Ρ 
<0.01 
<0.01 
<0.01 
n.s. 
<0.01 
<0.01 
<0.01 
<0.01 
DISCUSSION 
In everyday clinical practice a tendency is seen to use higher dosages 
of the antirheumatic drug naproxen. Many clinicians nowadays prescribe 
1000 mg daily, divided into one, two or three doses. The pharmacokine­
tics of naproxen have been described by Runkel et al (1973, 1974). 
Naproxen is completely absorbed from the gastrointestinal tract. After 
absorption it is highly bound to serum albumin. When the dosage is in­
creased above a certain level there is a disproportional, smaller in­
crease in serum level. From their data these authors concluded that 
dosage above 500 mg twice daily would be less advantageous from a phar­
macokinetic point of view, as with the higher dosage no appreciably 
higher serum levels would be reached. Because of more rapid excretion 
at higher plasma concentrations one might have expected a shorter 
t1/2p and a greater UEo-
>
.24 u P o n o nce daily dosing of 1000 mg 
naproxen. In fact we found a longer Μ/2β, and an U E Q . ^ only 
slightly larger than with twice daily dosing. The urinary excretion of 
naproxen metabolites represents only 60% of the dosage of 4.3 
mmol/daily (1000 mg = 4.3 mmol naproxen). Exceeding the capacity in the 
serum for albumin binding of a drug can be followed by an increase in 
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total body clearance and/or an increase of the volume of distribution. 
Our findings indicate that there is a greater increase of the volume of 
distribution and a smaller increase of total body clearance, resulting 
in the longer t1/2R found upon once daily dosing. The total body 
clearance of a drug is the sum of renal excretion, metabolic 
conversion, and possibly additional routes of elimination; for naproxen 
the renal excretion of native substance is negligible. Therefore, the 
increase in total body clearance upon once daily dosing must be caused 
by an increased metabolism. At the moment it is not possible to 
interpret these pharmacokinetic data in terms of clinical relevance. 
One report (Mowat et al, 1984) presents evidence, from a single blind 
comparison, that in rheumatoid arthritis a total dose of 1000 mg daily 
can be given either as 1000 mg once daily or at bedtime or 500 mg twice 
daily without compromising efficacy of safety, whereas in that study 
more patients expressed a preference for twice daily treatment. In the 
situation of a once daily gift, with the concomitant greater 
^Dextrap» o n e "light speculate that a larger amount of the drug is 
available for metabolism but also for distribution to the inflamed 
tissues. This could lead to a better analgesic effect, but also to 
higher occurrence of adverse experiences. Data from Day et al (1982) 
indicate that 16% of the rheumatoid patients have a good clinical 
response when the С£
гои
д|-, of naproxen is above 50 цд/ті; the serum 
level of the drug naproxen therefore seems to have some importance in 
terms of clinical effectiveness, and referring to this paper we choose 
the t[;>5Q and AUCQ
>
24· O50 ^ 0 describe the serum concentration 
profiles in the volunteers of the study. The tQ>5g turned out to be 
significantly longer upon twice daily dosing than with once daily 1000 
mg; this finding is paralleled with the difference in AUCQ
+
24· O50 
(590:500 цд/тІ/Ьг, ρ = 0.05). At a first glance one is tempted to 
conclude that volunteers and patients given 500 mg twice daily are 
optimally treated in comparison with the giving of the 24 
hours dose in one gift. On the other hand it has to be stressed that 
upon once daily dosing - let it be temporary - higher free, i.e. pro­
tein unbound concentrations of naproxen in the serun exists; this might 
explain why a once daily gift is effective at all, and probably might 
implicate that once daily dosing realizes an even better therapeutic 
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effect. To illustrate this line of thought figure 4 represents the cal­
culated individual Cf
r e e
 of naproxen in the plasma on the two dosage 
regimens; data of Runkel et al (1974) have been used to estimate the 
values for Cf
r e e
 from the total Cg values as calculated. In conclu­
sion: the twice daily regimen resulted in higher trough serum levels, 
larger AUCQ^24· O50· ^Dextrap anc' ^ 0 a lesser extent СІ£0£ were 
larger upon the once daily regimen with the longer tl/Zn as a conse-
quence. As yet one can only speculate about the therapeutic implica-
tions of these considerations. 
Cfree^g/nn|)Cfree 
1.8-
0.4 J 
1d.d. 
Figure 4. Estimated values for non-protein bound serum concentrations 
(Cfree) of naproxen in each subject; estimation from 
individual total Cg at steady state (see Methods) was made 
with data from the literature (Runkel et al, 1974) 
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Chapter 4 
ASSESSMENT OF DISEASE ACTIVITY IN ANKYLOSING SPONDYLITIS: 
THE COMMON CLINICAL CRITERIA AND AN INDEX OF DISEASE ACTIVITY 
MJAM Franssen, FWJ Gribnau, LBA van de Putte 
submitted for publication 
SUMMARY 
The construction and application of a composite index of disease acti­
vity (IDA) in ankylosing spondylitis (AS) is described, using data of 
3Θ male patients studied over 48 weeks on dominant spinal pain (DSP), 
morning stiffness (MS), chest expansion (CE) and lumbar flexion index 
(LFI). The presented IDA correlated with each of its components whereas 
between them correlations only partly existed. Moreover changes of IDA 
(ΔΙΟΑ) were frequently correlated with changes of the separate parame­
ter, and with parameters not included in the index, such as AESR, AlgA 
and patient's and investigator's overall assessments. This study demon­
strates that a composite index can easily be applied in assessing dis­
ease activity and response to therapy during a clinical trial. 
50 
INTRODUCTION 
Ankylosing spondylitis (AS) is a chronic inflammatory disease affecting 
mainly the sacroiliac joints and vertebral column, often leading to an-
kylosis. Patients suffer from back pain and stiffness, which is most 
troublesome at night and in the morning. Even in the early phase of the 
disease patients have a decreasing mobility, reflected by impairment of 
lumbar flexion and chest expansion. A well-balanced assessment of the 
various aspects of the inflammatory process, providing an overall 
judgement of disease activity, is difficult in this disease. Nor is 
there any single laboratory test which could be used as an objective 
parameter of disease activity in AS, as ESR and haemoglobin are used 
in rheumatoid arthritis. Collecting reliable data on separate signs of 
the disease process, and judging the individual's condition in terms of 
an integral conclusion, are important once again when the response to 
treatment has to be measured. Mallya and Mace (1) have described an in-
dex of disease activity (IDA) for patients with rheumatoid arthritis, 
providing a useful method to evaluate disease activity for longitudinal 
assessments, for drug trials, and for evaluation of possible new ob-
jective parameters. Recently Van Riel et al (2), using a modification 
of Mallya's IDA, were able to debcnbe the response to therapy during a 
single-blind trial comparing aurothioglucose and auranofin. Calm et al 
(3) used a composite index when comparing pirprofen and indomethacin in 
AS. The present study is aimed at constructing an index of disease ac-
tivity in AS in order to assess efficacy of treatment (therapeutic 
index) (4). 
METHODS 
Four parameters were used to calculate the IDA values: 
- dominant spinal pain (DSP) 
- morning stiffness (MS) 
- chest expansion (CE) 
- lumbar flexion index (LFI) 
DSP was defined as the most severe day-pain, as judged by the patient, 
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regardless of its location (cervical, thoracic or lumbar sacroiliac), 
using a 5-point scale ranging from 0 (no pain) to 4 (very severe 
pain). MS was reported by the patient in minutes or hours since aris-
ing. CE and LFI were measured by one investigator (MF) as described in 
the literature (5,6). For these parameters DSP, MS, CE and LFI, a divi-
sion was made into 5 grades of increasing seventy (table I), using the 
normal and pathological ranges given in the literature (3,6,7) for the 
latter three components. The individual's mean of the four graded para-
meters was used as IDA for that patient. 
Table 1. GRADING OF DSP, MS, CE AND LFI ACCORDING TO INCREASING 
SEVERITY 
DSP 
MS 
CE 
LFI 
(0-4) 
mm 
cm 
cm 
0 
0 
<10 
> 7 
> 7 
1 
1 
10-30 
6.9-5.0 
6.9-5.0 
2 
2 
31-60 
4.9-3.5 
4.9-3.5 
3 
3 
61-120 
3.4-2.0 
3.4-2.0 
4 
4 
>120 
<2.0 
<2.0 
The IDA of an individual patient is calculated as the mean of his score 
for the four respective components 
In addition, the investigator's opinion as to the overall degree of 
disease activity was noted at each visit, using a 4-point scale ranging 
from 0 (no signs or symptoms) to 3 (overwhelming symptoms) . At each 
visit the patients evaluated their overall response as compared with 
baseline using 5 categories (much better - better - unchanged - worse -
much worse). The investigator evaluated the patient's overall response 
to the trial medication, also using 5 categories (excellent - good -
fair - poor - none). 
The IDA was calculated with the data on 38 patients with AS, obtained 
during a drug trial of 48 weeks, comparing the efficacy and safety of 
diflunisal (DIF) and phenylbutazone (PBZ). The trial was preceded by a 
wash-out period of two weeks, whereupon patients were randomly alloca-
ted to receive one of the drugs. The first 12 weeks of the study were 
double-blind, followed by an open extension period of 36 weeks. 
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Nine patients dropped out, seven in the double-blind and two in the 
open period. The reasons were: 6 due to side effects and 2 due to in-
efficacy of treatment, equally distributed over the two groups, another 
patient was lost to follow-up. 
In the drug withdrawal period before the trial, the patient had to show 
a flare-up as evidence of disease activity when not treated with 
drugs. The flare-up was defined as a clinically demonstrable worsening 
of the patient's condition, in which pain was an essential component 
and reached a degree of seventy requiring therapy. Patients with a 
severe consolidated stage of the disease, i.e. multiple joint involve­
ment and total immobility of the spine, were excluded from the study. 
Assessments were made every 2 weeks in the double-blind, and every 4 
weeks in the open extension period; IDA was calculated at baseline and 
at weeks 12, 24, 36 and 48. Laboratory parameters relevant to this re­
port were: ESR at each visit and serum IgA at baseline and every 12 
weeks thereafter. 
The IDA and its four components were considered as continuous variables 
and assessed with regard to mean change from baseline. Between and 
within group changes were conducted using unpaired or paired Student 
t-tests as appropriate. Correlations were assessed using parametric 
correlation methods. 
RESULTS 
Table II shows correlations between DSP, MS, CE and LFI, and between 
each of these parameters and IDA. Of the separate components of IDA, 
only MS and DSP correlated significantly during treatment, whereas IDA 
always correlated significantly with all its contributing parameters. A 
comparison of the two treatment groups is given in figure 1, with the 
respective mean IDA before discontinuation of original treatment, at 
baseline, and at weeks 12 through 4Θ. At each time during active treat­
ment in the trial there was significant improvement in both groups as 
compared with base-line. No gross differences between DIE and PBZ 
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treatment were found. Both groups showed a flare-up, as their mean IDA 
(figure 1) at baseline differed significantly (p<0.05) from week -2. 
The individual values of IDA at weeks -2 and 0 are given in figure 2. 
It can be seen that some patients considered eligible for entering the 
study, had no increase in IDA at baseline. 
Table II. CORRELATIONS BETWEEN DSP, MS, CE AND LFI, AND BETWEEN EACH OF 
THESE AND IDA, AT WEEKS 0 THROUGH 48 (correlation 
coefficients) 
week 0 (n=38) MS CE LFI IDA 
DSP 0.12 0.19 0.07 0.21 
MS - 0.04 - 0.22 0.45** 
CE 0.46** - 0.64*** 
LFI - 0.77*** 
week 12 (n=32) 
DSP 0.41 * 0.12 0.12 0.55 ** 
MS 0.0B 0.17 0.40 * 
CE 0.46 ** - 0.51 ** 
LFI - 0.53 ** 
week 24 (n=29) 
DSP 
MS 
CE 
LFI 
week 36 
DSP 
MS 
CE 
LFI 
week 48 
DSP 
MS 
CE 
LFI 
(n=29) 
(n=29) 
0.48 ** 
0.60 *** 
0.50 ** 
0.06 
0.16 
0.02 
- 0.08 
- 0.29 
- 0.03 
0.05 
0.18 
0.27 
- 0.002 
0.15 
0.25 
- 0.27 
- 0.12 
0.27 
0.67 *** 
0.37 * 
- 0.45 * 
- 0.43 * 
0.72 *** 
0.46 * 
- 0.53 ** 
- 0.43 * 
0.81 *** 
0.52 ** 
- 0.55 ** 
- 0.54 ** 
n=number of patients, * p<0.05; ** p<0.01; *** p<0.001 
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I D A 
4-, о o PBZ 
π G DIP 
1 1 l i l i 
week -2 О 12 24 36 4 8 
F i g u r e 1 . Mean IDA v a l u e s o f b o t h t r e a t m e n t g r o u p s b e f o r e t h e t r i a l 
(week - 2 ) , a t b a s e l i n e (week 0) and d u r i n g drug t h e r a p y 
(weeks 12 t o 4 8 ) ; a l l v a l u e s were s i g n i f i c a n t i n compar ison 
w i t h b a s e l i n e 
ι 1 г 
2 3 4 
I.D.A. week О 
F i g u r e 2. I n d i v i d u a l IDA v a l u e s at weeks - 2 and 0 
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Figure 3 depicts the mean values of the four components (DSP, MS, CE, 
LFI) of the IDA throughout the study. In both treatment groups most 
values for DSP, CE and LFI were significantly better during treatment; 
MS also differed from baseline, but this never reached a level of sta-
tistical significance. A striking phenomenon was the lack of difference 
in mean CE and LFI at baseline, as compared with week -2. Nonetheless, 
at baseline IDA correlated with CE and LFI, as shown in table II. 
Dominant spinal pain 
(score) 
4 
3 
2H 
1 
Morning stiffness 
(minutes) 
300 
Chest expansion-
(cm) 
8-
Lumbar flexion index-
(cm) 
10-
I I 
12 24 36 48 
weeks 
-2 12 
I I I 
24 36 48 
weeks 
Figure 3. The course of IDA components DSP, MS, CE and LFI throughout 
the study; the open circles or squares indicate statistically 
significant (p<0.05) and the closed circles or squares indi-
cate non-significant (p>0.05) difference from baseline within 
a treatment group; the asterisks indicate significant differ-
ence between the treatment groups, all in favour of PBZ. 
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The charts in figure 4 present the individual IDA values at weeks 12 
and 48 respectively, as compared with baseline. One patient on PBZ 
showed no change after 12 weeks of therapy, whereas half the patients 
improved by <2b% change of baseline IDA, the other half >25%. Of the 
patients on DIF, two-thirds changed <25%, and one-third improved >25S. 
At week 48, again in comparison with baseline, three patients in both 
groups did not improve; a change of IDA <25% occurred in 30% in both 
treatment groups, and the difference was >25?ó in 50% of patients in 
I.DA. week О 
О 1 
I.D. A. week О 
τ г 
2 3 4 
I.D. A. week 12 
-500/ο - 2 5 % 0°/
с / 
I.D.A.week48 
Figure 4. Individual IDA values at weeks 12 and 48 in comparison with 
baseline; percentages represent degrees of decline of IDA 
values 
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TABLE III. CORRELATIONS BETWEEN CHANGES OF DSP, MS, CE, LEI, ESR, IgA 
AND IDA AS COMPARED WITH BASELINE THROUGHOUT THE STUDY 
(correlation coefficients) 
Week 0-12 ΔΜ5 
n=32 
ADSP 0.38* 
ΔΜ5 
ДСЕ 
ALF I 
AESR 
ДІдА 
Week 0-24, n=29 
ADSP 0.23 
AMS 
ACE 
ALF I 
AESR 
AlgA 
Week 0-36, n=29 
ADSP 0.45* 
AMS 
ACE 
ALFI 
AESR 
AlgA 
ACE 
-0.19 
-0.12 
0.10 
0.12 
0.14 
-0.01 
ALFI 
0.01 
-0.43* 
0.17 
-0.08 
-0.41* 
-0.26 
-0.14 
-0.38* 
-0.01 
AESR 
0.39* 
0.23 
-0.13 
-0.03 
0.30 
0.28 
-0.03 
-0.16 
0.39* 
0.20 
-0.07 
-0.15 
AlgA 
0.11 
0.25 
0.05 
-0.33 
0.28 
0.24 
0.35 
0.01 
-0.46* 
0.13 
0.29 
0.32 
-0.01 
-0.37* 
0.45* 
AIDA 
0.55** 
0.77*** 
-0.30 
-Ü.43* 
0.42* 
0.38* 
0.65*** 
0.49** 
-0.23 
-0.35 
0.56** 
0.54** 
0.66* 
0.63*** 
-0.32 
-0.46* 
0.39* 
0.41* 
week 0-4 , n=29 
ADSP 0.34 
AMS 
ACE 
ALFI 
AESR 
AlgA 
0.04 
-0.05 
-0.07 
-0.51** 
0.15 
0.07 
0.05 
0.02 
-0.05 
-0.03 
0.12 
-0.11 
-0.33 
0.58** 
0.57** 
0.68*** 
-0.30 
-0.55** 
0.17 
0.34 
* p<0.05, ** p<0.01, *** p<0.001 
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both groups. Four patients on PBZ improved >50?o, two of these were re­
cently referred cases not treated with NSAIDs at selection and there­
fore not indicated in figure 2. Finally, figure 5 depicts the indivi­
dual IDA values at weeks -2 and 48; it demonstrates a wide scatter of 
these values around the 0% line. 
1 D.A. week 
4η 
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• Í3 
• = 
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ι • 1 
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/ 
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о 
2 3 4 
I.D.A. week 48 
Figure 5. Individual IDA values weeks -2 and 48 
No correlation was found between absolute values of IDA and ESR, nor 
with IDA and IgA levels during treatment throughout the trial. The 
change in IDA (ΔΙΟΑ) on the other hand was significantly correlated 
with AESR and AlgA, and ΔΙΟΑ was also often correlated with the change 
in the other parameters, except ACE (table III). 
Table IV shows correlations between overall response to treatment eval­
uated by patient and investigator and ΔΙΟΑ, and correlations between 
IDA and values of overall disease activity assessed by the investiga­
tor at baseline and every 12 weeks during the study. The changes in IDA 
were always correlated with the overall response to treatment as evalu­
ated by the patient and mostly with the investigator's evaluation of 
the patient's response. The overall disease activity showed a signifi­
cant correlation with the IDA throughout the study. 
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Table IV. CORRELATIONS BETWEEN OVERALL RESPONSE TO TREATMENT AS 
EVALUATED BY PATIENT AND INVESTIGATOR, AND CHANGE OF IDA 
(AIDA) IN COMPARISON WITH BASELINE; AND CORRELATIONS BETWEEN 
IDA AND OVERALL DISEASE ACTIVITY 
Response patient 
Response investigator 
Overall disease activity 
AIDA 
-
IDA 
0.38* 
0.56*** 
0.36* 
0.54** 
0.74*** 
0.64*** 
0.61** 
0.38* 
0.29 
0.39* 
0.59*** 
0.39* 
0.61*** 
week 0 12 24 36 48 
η 38 32 29 29 29 
* p<0.05, ** p<0.01, *** p<0.001 
DISCUSSION 
In clinical practice, the physician assesses the disease activity in a 
patient with AS on the basis of data obtained from the clinical history 
(e.g. pain and stiffness), physical examination (e.g. chest expansion, 
lumbar flexion and tenderness of joints and entheses) and laboratory 
analyses (e.g. ESR and CRP). The value of the latter is questionable 
(8,9). In the view of the clinician the pain (e.g. DSP), stiffness 
(MS), and impaired mobility (decreased CE and LFI) are essential parts 
of the physiognomy of AS, and therefore important as parameters if the 
condition of a patient is judged. One might expect that all these para­
meters would correlate significantly, but, as shown in table II, only 
DSP and MS are significantly correlated during treatment of AS. The 
clinical relation between DSP, MS, CE and LFI on the one hand, and the 
absence of statistical correlation among these parameters on the other 
hand, allows combining them in an IDA. The statistical significance of 
the correlation of this IDA with each of its components justifies its 
use for studying a population of patients in a drug trial. 
Results of therapeutic intervention are often presented as comparisons 
with a baseline situation. This baseline is achieved by a period of 
withdrawal from previous medication. In studies on antirheumatic drugs 
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a flare-up after wash-out is a common criterion for inclusion. Obvious-
ly the pre-baseline values (week -2 in figure 1 and 3) give important 
information on the various aspects of the flare-up of the disease. The 
mean values of CE and LFI at baseline were not different from pre-trial 
values (figure 3). With regard to this aspect of disease, withdrawal 
from treatment did not result in changes of mobility during a two-week 
wash-out period. The IDA presented might give a correct description of 
the course of disease during active treatment (figures 1 and 4), but it 
cannot be used as selection criterion before entering a study, when the 
needed flare-up has been defined as primarily concerning pain (figure 
2). 
This trial showed that drug treatment achieves a reduction of the IDA 
by a certain percentage (figure 4), and not reduction to an always-to-
be-reached, attainable level, independent of baseline IDA. Because the 
patients studied differed in seventy and extent of their disease, the 
trial outcome and a judgement of the IDA as a therapeutic index depend 
not only on drug effect but also on residual impairment and on a vary-
ing course of the disease itself. Therefore, comparison of IDA at week 
-2 with week 48 allows only a conclusion about the course of drug-
treated ankylosing spondylitis (figure 5). Regular intake of drugs at a 
trial dosage versus less optimal compliance or a lower dosage in every-
day practice, might cause a difference between the effect of trial the-
rapy and that of pre-trial treatment with the same drug. This differ-
ence can only be demonstrated by giving data on the pre-trial period. 
Examination of the individual data from the best responders on PBZ in 
figure 5 did not enable us to explain their excellent response in this 
way. 
In this trial, as in most other studies, global assessments were made: 
overall response to treatment in comparison with baseline, as judged by 
both patient and investigator, and overall disease activity as judged 
by the investigator. It is clear that these assessments pose special 
problems, because patients are unable to remember accurately how they 
felt at baseline, increasingly distant in time. Moreover, disease-unre-
lated factors could be involved in the decision made about these para-
meters. Nevertheless, as table IV shows, these overall assessments did 
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correlate with AIDA and IDA respectively. Despite this correlation, we 
still would prefer the described IDA as a measurement of the overall 
disease state, because its components reflect the most relevant patient 
complaints (pain and stiffness) and a relevant, objectively measured, 
main disease effect (impaired mobility). The measurements needed are 
simple and better reproducible than overall assessments. Admittedly, as 
Bacon has pointed out in discussing combined and compound assessment 
indices (10), a decrease in sensitivity and loss of relevant detail 
might result from using such a combination of assessments. On the other 
hand only the use of a group of well-chosen parameters together will be 
able to provide an overall figure on disease activity. 
In a clinical trial it is essential to find the demonstrated correla-
tions between AIDA and the changes of its components (table III); of 
the separate parameters only AMS and ALFI were correlated. Since a re-
lation has been found between raised IgA serum levels and active dis-
ease in AS (11,12,13), it was also important to find a significant cor-
relation between AlgA and AIDA. ESR was not included in the IDA; its 
value as a parameter in AS is under dispute (8,9,12). Anyhow, we found 
the same correlation between AESR and AIDA as for AlgA. Serial X-rays 
were not taken into account as contributing to the IDA, because the 
period of observation was relatively short: 48 weeks. 
In table V an attempt is made to compare our IDA with IDAs calculated 
from some data in the literature (14,15,16,17), using our scale of 
grading (table I) for the reported mean group data. It may be concluded 
that comparable selection criteria were used, and the outcome of 
therapy was of the same order in the different locations. 
It is obvious that, for studying drug efficacy, its pharmacological 
action dictates the choice of IDA components. When merely analgetic 
treatment for AS would be given, it would not be realistic to include 
mobility assessment in an IDA automatically. At this time it is not 
possible to decide on an optimal number or collection of parameters for 
clinical trials in AS. Such an optimun would be attractive, above all 
to prevent unnecessary work. Finally, it is important to bear in mind 
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Table V. IDA CALCULATIÜNS FROM DATA OBTAINED IN THE LITERATURE 
Studies 
Calm et al, 
1974 (14) 
Jessop, 
1976 (15) 
Mena et al, 
1977 (16) 
Esdaile et al, 
19Θ2 (17) 
This study 
Base­
line 
2.38 
2.71 
2.36 
2.89 
2.10 
2.73 
3.08 
3.30 
3.20 
2.40 
2.60 
Treatment 
PBZ IND 
1.95 
2.33 
2.10 
2.55 
1.70 
1.60 
FBN TMN DIF KPN 
2.28 
2.33 
2.64 
2.13 
2.13 
2.00 
η 
35 
12 
8 
12 
8 
13 
9 
55 
55 
15 
17 
duration 
weeks 
4 
4 
4 
4 
4 
6 
6 
12 
12 
12 
12 
PBZ = phenylbutazone, IND = indomethacin 
FBN = flurbiprofen, TMH = tolmentin 
DIF = diflumsal, KPN = ketoprofen 
that trial patients continue to be patients in the usual sense. Whether 
drug trial subject or not, the patient asks for attention to his indi­
vidual complaints, including his report of his overall condition, and 
for assessment of his individual disease consequences. Reduction of the 
number of trial parameters for reasons of trial economy therefore does 
not allow a reduction of the clinically required collection of indivi­
dual data. 
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Chapter 5 
A COMPARISON OF DIFLUNISAL AND PHENYLBUTAZONE IN THE 
TREATMENT OF ANKYLOSING SPONDYLITIS 
MJAM Franssen, FWJ Gribnau, LBA van de Putte 
accepted for publication 
Clinical Rheumatology 
SUMMARY 
A 12 week double-blind randomized drug trial followed by an open exten-
sion period of 36 weeks was carried out in 38 male patients with anky-
losing spondylitis (AS) to compare the efficacy and safety of difluni-
sal (500 mg twice daily) and phenylbutazone (200 mg twice daily). Both 
drugs proved to be effective in improving the severity of symptoms 
associated with AS, and this improvement was maintained throughout the 
open extension period. Initially diflunisal had a more pronounced and 
rapid analgesic action, whereas phenylbutazone was more effective in 
increasing axial mobility. 
During the study 9 patients dropped out: 3 in each treatment group due 
to side effects and 1 in each group due to lack of efficacy, another 
patient was lost to follow-up. The two drugs were similarly safe as 
judged by the occurrence of adverse clinical effects, mainly gastroin-
testinal. This study again demonstrates the value of phenylbutazone in 
AS but, taking into account the possible haematological side effects, 
the use of other NSAIDs is stressed. Diflunisal is an alternative capa-
ble of improving the painful stiffness associated with AS. 
The usefulness of an index of disease activity (IDA) presented in this 
study is discussed. 
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INTRODUCTION 
Ankylosing spondylitis (AS) is a disease characterized by an inflamma­
tion of the axial skeleton leading to ankylosis. This inflammation 
causes a painful stiffness, which is aggravated during rest and is most 
troublesome at night and in the early morning. Painful muscle and liga­
ment insertions (enthesitis) and bone tenderness are common symptoms 
associated with the disease. The aim of drug treatment in AS is to en­
sure analgesia and to maintain normal mobility and posture. Only phe­
nylbutazone (PBZ), has been claimed to modify the inflammatory process 
per se (1). 
For many years this particular drug has been regarded as the standard 
drug in the treatment of AS. Later on, PBZ proved to be associated with 
haematological complications, primarily agranulocytosis in younger pa­
tients and aplastic anaemia in older age groups (2). This finding has 
led to withdrawal of PBZ from the market in some countries or its re­
servation for strictly defined indications. The newer NSAIDs indometha-
cin (3) and naproxen (4,5) became effective and well tolerated alterna­
tives to PBZ, also in AS. Acetylsalicylic acid was less effective in AS 
(6) than the NSAIDs just mentioned. A few years ago the new salicylic 
acid derivative diflumsal (DIP) was introduced, which possesses both 
anti-inflammatory and analgesic properties with a longer half-life and 
greater anti-inflammatory potency than salicylic acid (7). The efficacy 
of, and tolerance to DIF in patients with osteoarthritis (Θ), rheuma­
toid arthritis (9,10) and gout (11) has been demonstrated in several 
comparative studies using a maximum of 1000 mg daily. In view of the 
analgesic and anti-inflammatory properties of DIF and its long duration 
of action, a comparison of DIF with PBZ in the treatment of AS was 
carried out. The study was designed as a 12-week double-blind drug 
trial, followed by an open extension period of 36 weeks. 
PATIENTS AND METHODS 
The study concerned male patients aged between 18 and 55 years, with 
definite AS (12) confirmed by two or more of the following symptoms: 
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back pain, morning stiffness and progressive limitation of movement. 
Patients were admitted only when they showed a flare-up during or after 
a drug withdrawal period of 14 days. A flare-up was defined as a worse­
ning of the patient's condition in which pain and stiffness was an 
essential component, requiring treatment. 
Excluded were patients with an active peptic ulcer or with other signi­
ficant internal or neurological disease. Patients who were hypersensi­
tive or showed serious side effects while taking NSAIDs were not ad­
mitted. Patients who had an end-stage and incapacitating disease (ARA 
functional class IV) (13) were also excluded. 
After a drug-free period of 14 days, or less if a flare-up developed 
earlier, all patients were allocated at random to receive either DIF 
500 mg twice daily or PBZ 200 mg twice daily for 12 weeks according to 
a double-blind design. Patients received only one active compound to­
gether with the corresponding placebo of the alternative drug. Any pro­
gramme of physical therapy remained unchanged during this double-blind 
period. In the subsequent open extension period of 36 weeks the dose of 
both drugs could be adjusted on the basis of the individual's disease 
activity, and physical therapy could be added if necessary. No other 
drug intake was allowed during the study except 500 mg acetaminophen as 
a supplementary analgesic, the amount of which was recorded during each 
visit. Patients were seen bi-weekly in the double-blind and at 4-week 
intervals in the open period. All clinical evaluations were performed 
by one investigator (MF) between 13.00 and 16.00 o'clock. 
At each visit the following parameters had been assessed by the pa­
tient: spinal pain (cervical, thoracic and lumbar sacroiliac regions) 
and night pain using a 5-point scale ranging from 0 (no pain) to 4 
(very severe pain). Furthermore, the duration of morning stiffness 
since arising had been recorded. An upper limit of θ hours was chosen 
as definition of morning stiffness to minimize the variation associated 
with this parameter by some patients claiming their morning stiffness 
lasted all day. Patient evaluation was based on the worst score record­
ed during two days prior to each visit. The investigator evaluated spi­
nal tenderness (cervical, thoracic and lumbar sacroiliac regions) using 
the same scale as defined above. He also counted the number of tender 
entheses and tender or inflamed joints. Furthermore, chest expansion 
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(14), lumbar flexion index (15), occiput-to-wall and finger-to-floor 
distance were measured. The investigator's opinion as to the overall 
degree of disease activity was noted at each visit using a 4-point 
scale ranging from 0 (no signs or symptoms) to 3 (overwhelming symp-
toms) . At each visit the patients evaluated their overall response as 
compared with baseline, using 5 categories (much better-better-
unchanged-worse-much worse). The investigator evaluated the patients' 
overall response to the trial drugs, also using 5 categories 
(excellent-good-fair-poor-none) ; for the purpose of calculating corre-
lations these response categories were valued as 0 through 4. The res-
ponse to treatment was also judged by an index of disease activity 
(IDA) (16) based on 4 parameters: dominant spinal pain (DSP, being the 
most severe spinal pain, regardless of its location), morning stiffness 
(MS), chest expansion (CE) and lumbar flexion index (LFI), graded as 
shown m table I. The mean grade of these patient values across the 
four parameters for each individual was taken as the IDA of that pa-
tient. The seventy (mild-moderate-severe) of side effects was also no-
ted by the investigator. 
Blood tests were done at each visit (ESR, haemoglobin, WBC, platelet 
estimate, Creatinin, alkaline phosphatase, creatine Phosphokinase, uric 
acid) and a urinalysis was performed. Serum immunoglobulin levels were 
measured every 12 weeks. 
A slit-lamp eye examination was carried out on nine occasions during 
the study to detect early anterior uveitis. A spirometrie examination 
was performed at baseline and at weeks 12 and 48. Vital capacity mea-
surements were compared with standard normal values from the literature 
Table I. GRADING OF DSP, MS, CE AND LFI ACCORDING TO INCREASING 
SEVERITY 
0 1 2 3 4 
DSP (0-4) 0 1 2 3 4 
MS min <10 10-30 31-60 61-120 > 120 
CE cm > 7 6.9-5.0 4.9-3.5 3.4-2.0 < 2.0 
LFI cm > 7 6 . 9 - 5 . 0 4 . 9 - 3 . 5 3 . 4 - 2 . 0 < 2.0 
The IDA of an individual patient is calculated as the mean of his 
score for the four respective components 
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(17). An audiogram was made at baseline and at the end of the open pe-
riod. 
Returned tablet counts, to check for patient compliance, were used du-
ring the double-blind period. Moreover, at each visit blood sample: 
were taken for determination of steady state serum DIP and PBZ level: 
to monitor therapy compliance throughout the trial. 
Pain variables were considered as continuous and together with othei 
efficacy variables, statistical tests were carried out on the mear 
changes from baseline (week 0). Between and within group tests wen 
conducted using upaired or paired Student t-tests as appropriate. Be-
tween group comparisons for global response variables were performet 
using a generalised linear model for a weighted sum of the frequencies 
in the various response categories. Correlations were assessed usine 
parametric correlation methods. Fisher's exact test was used to compare 
the groups with regard to the incidence of adverse experiences. 
Verbal informed consent was obtained from all patients. The study was 
approved by the Ethics Committee of the Medical Faculty of the Univer-
sity of Nijmegen. 
RESUtTS 
Thirty-eight male patients, ranging in age from 20 to 54 years (mean 3" 
years) took part in the study. Each treatment was taken by 19 pa-
tients. Thirty-one patients (14 in the DIF and 17 in the PBZ group] 
completed the double-blind phase and entered the open study period. At 
the end of the study, at week 48, 14 DIF and 15 PBZ taking patients 
were eligible for analysis. Three patients in each group withdrew due 
to adverse experiences, one patient in each group discontinued the 
trial due to ineffective therapy and one patient on DIF was lost tc 
follow-up. 
As shown in table II, both groups were similar regarding demographic 
and disease characteristics and previous therapy with PBZ. There were 
no significant differences in clinical efficacy parameters between the 
two treatment groups at baseline (table III). The values of ESR and Ig/ 
were significantly higher in the DIF group (p<0.05, table IV). 
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Table I I . BASELINE DEMOGRAPHIC AND DISEASE CHARACTERISTICS 
Number o f p a t i e n t s 
Age ( y e a r s ) 
mean 
range 
Disease d u r a t i o n ( y e a r s ) 
mean 
range 
P r e v i o u s t h e r a p y 
p h e n y l b u t a z o n e 
Presence o f HLA B27 a n t i g e n 
d i f l u n i s a l 
19 
3 6 . 6 
20 - 54 
9.2 
1 - 21 
16 
19 
p h e n y l b u t a z o n e 
19 
3 7 . 0 
21 - 49 
9 . 4 
1 - 21 
16 
17 
SPINAL PAIN 
PATIENT INVESTIGATOR 
DOMINANT SPINAL PAIN 
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^ _ ^ i i m h a r 
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Figure 1. Venn diagram of the locations of spinal pain and dominant 
spinal pain as evaluated by patient and investigator at base-
line 
Table III. PATIENT'S AND INVESTIGATOR'S EVALUATION OF THE TREATMENT WITH DIFLUNISAL AND PHENYLBUTAZONE, 
AS COMPARED WITH BASELINE AT WEEKS 12 AND 48 (means ± SD) 
Diflunisal Phenylbutazon 
week 4Θ 
14 
week 12 
14 
week 0 
14 no. of patients 
week 0 
17 
week 12 
17 
week 48 
15+ 
Patient's evaluation 
1.6 ± 0.9** 1.6 ± 0.8** 2.8 ± 0.6 dominant spinal pain 2.6 ± 0.7 1.6 ± 1.0** 1.5 ± 1.2** 
1.6 ± 1.0* 1.4 ± 0.9** 2.4 ± 1.1 lumbar sacroiliac pain 2.3 + 0.9 1.5 ± 0.9* 1.3 ± 1.1* 
0.8 ± 1.0* 1.1 ± 1.1 1.8 ± 1.3 night pain 2.1 ± 1.3 0.8 ± 1.1* 0.8 ± 1.1* 
1.4 ± 1.3 1.2 ± 0.9 2.1 ± 2.0 morning stiffness (hrs) 2.7 ± 2.5 1.5 ± 2.0 2.0 ± 2.7 
Investigator's evaluation 
0.8 ± 1.0 0.7 ± 1.0* 1.2 ± 1.1 lumbar sacroiliac pain 1.8 ± 1.2 1.0 ± 1.0** 0.8 ± 1.1* 
4.0 ± 2.5* 3.7 ± 2.1* 3.5 ± 2.1 chest expansion (cm) 3.4 ± 1.6 4.5 ± 1.7** 5.1 ± 1.6** 
4.2 ± 2.2 4.3 ± 2.3 3.8 ± 1.9 lumbar flexion index (cm) 3.9 ± 2.4 5.0 ± 1.9* 5.1 ± 1.9* 
81 ±13 81 ± 15 81 ± 13 vital capacity^ predicted) 90 ±15 88 ± 14 86 ± 17 
0.7 ± 0.6** 0.8 ± 0.6** 1.4 ± 0.7 overall disease activity 1.9 ± 0.7 0.8 ± 0.7** 0.9 ± 0.9** 
2.1 ± 0.6** 2.1 ± 0.5** 2.6 + 0.5 index of disease activity 2.4 ± 0.7 1.7 ± 0.7** 1.7 ± 0.8»* 
+ ρ values obtained by paired t testing; * ρ <0.05, ** ρ <0.01 
The distribution of spinal pain location at baseline as evaluated by 
both patient and investigator, is presented In the upper Venn diagram 
in figure 1. Patients were identified regardless of seventy of pain at 
one, two or all locations. There were no differences between the two 
treatment groups, nor between patient and investigator assessments. The 
distribution of the location of the most severe spinal pain in each in-
dividual - the dominant spinal pain (DSP) - as judged by patient and 
investigator at baseline, is presented in the lower Venn diagram in fi-
gure 1. Most patients located their DSP in the lumbar sacroiliac re-
gion; the treatment groups were not different in localization of spinal 
pain. The investigator assessed twice as much thoracic pain as did the 
patients. The findings for selected clinical efficacy parameters at 
week 0, 12 and 48 are summarized in table III. 
Laboratory data which indicate efficacy or safety of the two drugs are 
shown m table IV. Figure 2 represents the course of two patient para-
meters, lumbar sacroiliac pain and night pain, and two investigator pa-
rameters, chest expansion and lumbar flexion index . Both treatment 
groups generally showed improvement in most efficacy parameters at each 
visit during the double-blind period, and this improvement was main-
tained or continued to increase during the open extension period. A 
level of statistical significance was often reached. In the patient's 
evaluation there were no significant differences between treatment test 
results, but in the investigator's evaluation significant differences 
between the treatments were observed at week 10 for lumbar sacroiliac 
pain, at weeks 2,8,12,32,36,40 for chest expansion and at week 28 for 
the lumbar flexion index, all in favour of PBZ. Cervical pain and tho-
racic pain, not mentioned in the tables, decreased in both treatment 
groups as judged by patient and investigator. Occiput-to-wall and 
finger-to-floor distance showed some but not statistically significant 
improvement in both groups. Although both thoracic pain and chest ex-
pansion improved, spirometrie findings revealed no change in vital ca-
pacity either during the double-blind or during the open period (table 
III). Data on the number of patients with tender enthesos and joints, 
and on the total number of tender entheses and painful joints during 
the double-blind period are given in figure 3. About half the patients 
in both groups had a tender enthesis at several sites at baseline. At 
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Table IV. LABORATORY DATA AT WEEKS 12 AND 48 AS COMPARED WITH BASELINE FOR THE TWO TREATMENT GROUPS 
(DIF and PBZ) 
week 48 
14 
Diflunisal 
week 12 
14 
week 0 
14 no. of patients 
week 0 
17 
Phenylbutazone 
week 12 
17 
week 48 
15+ 
20 ±22* 
9.0 ±0.7* 
80 ±15 
0.24±0.06** 
77 ±21 
59 ±17 
3.1 ±1.6* 
20 ±19** 
9.0 ±0.5* 
83 ±13* 
0.24±0.06** 
83 ±24 
74 ±36 
3.4 ±1.5 
31 ±20 
8.6 ±0.5 
75 ±22 
0.35±0.07 
88 ±27 
60 ±26 
3.6 ±1.5 
ESR (mm/hr) 
Hb (mmol/1) 
Creatinin (pmol/l) 
uric acid (mmol/1) 
19 ±12 
8.8 ±0.7 
77 ±8 
0.32±0.09 
a l k a l i n e phosph. (U/1) 90 ±31 
CPK (U/1) 92 ±65 
IgA (g/1) 2.9 ±1.4 
17 ±14 
8.4 ±0.7* 
67 ±23 
0.19±0.06** 
85 ±24 
76 ±40 
2.8 ±1.2 
17 ±13 
8.7 ±0.9 
78 ±8 
0.21±0.08** 
88 ±26 
65 ±23 
2.8 ±1.2 
+
 ρ values obtained by paired t testing; * p<0.05, ** p<0.01 
Lumbar sacroiliac pain 
score 
Chest expansion 
cm open extension 
period 
ш= 
i L 1 
Lumbar flexion index-
-° PBZ 
-o DIF 
week- 2 12 24 36 48 
Figure 2. The course of two patient parameters (lumbar sacroiliac and 
night pain) and two investigator parameters (chest expansion 
and lumbar flexion index) throughout the study. The open 
circles or squares indicate statistically significant 
(p<0.05) and the closed circles or squares indicate not sig­
nificant (p>0.05) differences from baseline within a treat­
ment group; the asterisks indicate significant differences 
between the treatment groups, all in favour of PBZ. 
week 12, 35% of patients on PBZ and 30% of those on DIF showed this 
disability. No manifest peripheral arthritis was observed during the 
study. Most of the arthralgias were localized in the acromioclavicular 
and sternoclavicular joints. 
In both groups a decrease in overall disease activity, as judged by the 
investigator, was found throughout the study as compared with baseline 
(table III). Table V shows the patient and investigator assessments of 
overall response. Data on correlations between IDA and ΔΙΟΑ respective­
ly, and overall disease activity and response to treatment are given in 
Table VI. 
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Number 
TENDER ENTHESIS 
PHENYLBUTAZONE 
weeks 0 2 4 6 8 10 12 
DOUBLE-BLIND PERIOD 
0 
TENDER JOINTS 
0 2 4 6 8 10 12 
DOUBLE-BLIND PERIOD 
I No. of patients 
J No. of tender sites 
DIFLUNISAL 
Eigure 3. Number of patients with tender entheses and joints, and num­
ber of tender entheses and joints 
Table VI. CORRELATIONS BETWEEN OVERALL RESPONSE TO TREATMENT AS 
EVALUATED BY PATIENT AND INVESTIGATOR, AND CHANGE OF IDA 
(AIDA) IN COMPARISON WITH BASELINE; AND CORRELATIONS BETWEEN 
IDA AND OVERALL DISEASE ACTIVITY. 
AIDA 
Response patient 
Response investigator 
0.56*** 0.74*** 
0.36* 0.64*** 
0.38* 
0.29 
0.59*** 
0.39* 
IDA 
O v e r a l l d i s e a s e a c t i v i t y 0 . 3 8 * 
week 0 
η 38 
0 . 5 4 * * 
12 
32 
0 . 6 1 * * 
24 
29 
0 . 3 9 * 
36 
29 
0 . 6 1 * * * 
48 
29 
p<0.05, ** p<0.01, p<0.001 
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Table Va. PATIENTS' OPINION OF OVERALL RESPONSE TO THERAPY AS COMPARED WITH BASE-LINE 
Week Treatment Response category 
much better better unchanged worse much worse 
12 DIF (n = 14) 2 10 2 0 0 
PBZ (n = 17) 4 9 4 0 0 
48 DIF (n = 14) 0 13 1 0 0 
PBZ (n = 15) 1 12 2 0 0 
Table Vb. INVESTIGATOR'S ASSESSMENT OF OVERALL RESPONSE TO TREATMENT 
week treatment Response category 
excellent good fair poor none 
12 DIF (n = 14) 5 7 1 0 1 
PBZ (n = 17) 8 4 2 2 1 
48 DIF (n = 14) 9 4 1 0 0 
PBZ (n = 15) 9 2 2 2 0 
^J 
^J 
Figure 4 charts the changes in individual IDA values from week D to 
week 12 and 48 respectively, and illustrates the composition of the 
trial population and its response in terms of the individual patient. 
Figure 5 shows the significant (p<0.05) changes in the clinical effica­
cy parameters as compared with baseline at each visit for both drugs. 
DA. week О 
Ί г 
0 1 2 3 4 
I.D.A.week 12 
I D A week 0 
-500/ο -25%, 0o/, 
2 3 4 
I DA. week 48 
Figure 4. Changes in the individual IDA values from week 0 to week 12 
and 4Θ respectively 
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evaluation 
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2 4 6 8 10 
1 J 1 I 1 
12 
ι 
] 
ііШІШІ11
 ^ ! еШШЗД 
^ g ^ Я 
Week of investigation 
' Cervical pain 
Thoracic pain 
Lumbar sacroiliac pain 
Night pain 
к Morning stiffness 
S Cervical pain 
Thoracic pain 
Lumbar sacroiliac pain Investigator s I 
evaluation <, Chest expansion 
Finger-floor distance 
Occiput-wall distance 
\ Lumbar flexion index 
I phenylbutazone Ì significant within t rea tment test results 
diflunisal ƒ compared with baseline 
* significant between treatment test results in favour of PBZ 
Figure 5. Significant changes (p<0.05) in clinical efficacy parameters 
as compared with baseline at each visit, for both drugs; 
between group differences, indicated with asterisks, were 
statistically significant (p<0.05) 
Significant differences between therapy groups occurred rarely and fa-
voured PBZ. For the purpose of establishing clinical relevance, figure 
6 depicts the clinically significant changes, defined as a decrease of 
the dominant spinal pain score by at least one grade, and an improve-
ment of both chest expansion and lumbar flexion index by one cm or 
more. Initially, a larger percentage of DIF patients than of PBZ pa-
tients showed clinically significant amelioration of the DSP, while the 
reverse applies to improvement of mobility. 
In each group one patient dropped out due to lack of efficacy (table 
VII). One patient on DIF had a worsening of mainly his thoracic and 
night pain and dropped out at week 10. One patient on PBZ showed no im-
provement and he stopped medication at week 20. During the double-blind 
period 4 patients on PBZ and 2 on DIF temporarily took additional ace-
taminophen tablets, up to 4x500 mg daily, but none reported distinct 
additional alleviation of pain. In the open extension period none of 
the patients used additional acetaminophen medication, but five pa-
tients on PBZ and four on DIF started physical therapy at some time du-
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DIFLUNISAL 
Patients 
"Ιο η . 17—15 
100 
15—14-14 
100-
0/o η = 19—17—17—16-
Patients 
-17—17 
PHENYLBUTAZONE 
Figure 6. Presentation of trial outcome in terms of clinical 
relevance. The first bar represents the percentage of 
patients with reduction of dominant spinal pain by 1 (open 
bar) or 2 (black part of bar) points; the second and third 
bars represent the percentage of patients with an increase of 
CE and LF1 by at least one cm. 
ring this period. In the open period the dosage of PBZ could be reduced 
to 200-300 mg daily in 4 patients and that of DIF to 500 mg daily in 1 
patient on a regular basis and in 4 others only for some weeks. 
The two treatment groups were similar in incidence and severity of side 
effects and no serious adverse experience occurred during the study. 
Table VII also summarizes the side effects and specifies the drop-outs 
for this reason. Most adverse experiences were only mild to moderate in 
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Table VII. SUMMARY OF SIDL· tFFLCTS AND DROP-OUTS THROUGHOUT THE TRIAL 
Side effect 
mouth ulcers 
gastric discorri 
pyrosis 
gastric pain 
loose stools 
diarrhea 
constipation 
vertigo 
drowsiness 
pruntis 
weight gain 
ifort 
lack of efficacy 
lack of cooper ation 
Numb 
pati 
DIF 
1 
2 
3 
1 
1 
2 
0 
2 
1 
2 
0 
er of 
ents* 
PBZ 
0 
2 
2 
2 
1 
0 
1 
2 
2 
0 
3 
-
-
Number of 
drop-
DIF 
_ 
-
-
1 
-
2 
-
1 
-
-
0 
1 
1 
-outs** 
PBZ 
_ 
-
-
2 
-
0 
-
1 
-
-
1 
1 
-
Week 
drop-
DIF 
4 
2,2 
4 
-
10 
2 
of 
-out 
PBZ 
2,16 
-
2 
2 
20 
-
* Some patients had more than one side effect at one time 
** Some patients dropped out because of a combination of gastric pain 
and vertigo, making the total number of drop-outs 9, of which 6 are 
due to adverse experiences 
seventy, and transient. Nearly half the patients in each group report-
ed a side effect associated with the gastrointestinal tract. One pa-
tient on DIF, who was found to be lactase-def icient, withdrew due to 
diarrhea, which may have been caused by the lactose contained in the 
PBZ placebo tablets. Only at week 4 a significant increase in supine 
systolic blood pressure in the PBZ group was found (mean change from 
base-line 6.7 ± 11.5 mmHg), without a change in supine diastolic blood 
pressure. A transient increase in body weight was also found in the 
PBZ group at weeks 2 and 4 (maximum mean change 1.3 ± 1.0 kg). One pa-
tient with a weight gain of 5 kg withdrew at week 2 due to edema. As 
to laboratory safety parameters, we found a significant increase in 
mean creatinine in patients on DIF at week 12, with a decline there-
after (table IV). 
Two patients on DIF developed iridocyclitis in the open extension 
period. In both cases the therapy was effective without side effects 
and both patients had experienced uveitis when on PBZ medication in the 
past. DIF was therefore not withdrawn, and both patients recovered 
without seguelae after ophthalmological treatment. In no other patient 
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was uveitis found, either subclinical or manifest. The audiograms made 
on two occasions did not change. 
The average patient compliance in the double-blind period was 95 ± й% 
for DIF and 96 ± 5% for PBZ (expressed as number of tablets taken di­
vided by number of tablets prescribed, times 100%). Moreover, in pa­
tients treated with the same dosage of PBZ and DIF in the open period 
as in the blind phase of the study, only minor differences in the 
series of drug serum levels were found. 
DISCUSSION 
Physical therapy and medication with a NSAID are the keystone of treat­
ment in AS. PBZ has proven to be an effective drug in this illness 
since 1952, and indomethacin was added to this in 1963. Both drugs were 
the most widely used NSAIDs in AS for many years. The occurrence of 
side effects, some serious, led to a search for other effective and 
safer drugs. Naproxen proved to be a good alternative (4,5). Salicylic 
acid derivatives have never become drugs of choice in AS. Diflumsal is 
a salicylic acid derivative with greater anti-inflammatory potential, a 
longer duration of action and fewer side effects than equivalent dos­
ages of acetylsalicylic acid (7). In postoperative pain (18), osteoar­
thritis (8) and rheumatoid arthritis (9,10) its analgesic action has 
been well established. In this study we compared the effects of diflu­
msal 500 mg twice daily with those of phenylbutazone 200 mg twice 
daily in the treatment of AS during a period of 48 weeks, divided into 
a double-blind phase of 12 weeks and an open phase of 36 weeks. 
Both drugs were generally effective in reducing pain and in improving 
impaired mobility associated with this disease, and both were well-to­
lerated and similarly safe. 
A striking phenomenon was the fact that - although CE and LFI did not 
decrease substantially upon flare-up - both parameters increased during 
therapy as compared with baseline. Probably this was caused by the fact 
that most patients had previously taken medication only on demand and 
- in the case of PBZ - often at a lower dosage. Improvement of CE and 
LFI during the study could therefore be related to a regular intake of 
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NSAIDs, as reflected by the reported 9b% patient compliance. 
So far as the clinical parameters (Table III and Figure 2) are concern-
ed, both treatment groups were comparable. The laboratory data on the 
other hand showed significantly higher ESR and serum IgA values at 
baseline in the DIF group (Table IV), despite the random allocation. 
Different effects of therapy on these two parameters were therefore 
probably due to baseline differences rather than to differences in 
therapeutic efficacy. 
As already stated, both drugs were capable of improving the patient's 
condition and there were no consistent statistical differences between 
the two groups. The improvement of CE was an exception: at several time 
points of evaluation (Figure 2 and 5) there was a better response of 
this parameter in the PBZ group (Figure 2). Thus the improvement of CL 
would favour PBZ, but in diminishing pain and morning stiffness DIF and 
PBZ were equally effective from a statistical point of view. 
In drug studies in rheumatic diseases the overall disease activity 
(physician) and overall response to therapy (patient and physician) are 
usually assessed by comparison with a baseline state obtained after me-
dication withdrawal. Both assessments include, be it in a non-quantita-
tive way, impressions of spinal pain and stiffness combined with mobi-
lity impairment. This way of assessing has two drawbacks: only an over-
all evaluation is made and patient and physician have to compare with a 
baseline value increasingly distant in time. A method of overall evalu-
ation including these separate parameters in a quantitative way, would 
be more appropriate and more accurate as well. We therefore constructed 
an index of disease activity (IDA) consisting of DSP and MS as assessed 
by the patient, and CE and LFI as assessed by the investigator. The DSP 
was chosen, because in some patients the most severe pain was localized 
not in the lumbar sacroiliac but in the thoracic and cervical regions 
(Figure 1). This IDA could easily be used to describe the individual 
outcome during the trial (Figure 4). The shown individual data at weeks 
12 and 48, respectively, were produced without need for patient and 
investigator to compare with baseline values. 
Somewhat as a surprise, when correlating IDA and AIDA respectively with 
overall disease activity and response to treatment (Table VI) we found 
significant correlations. It should be noted, however, that the overall 
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response as judged by the physician gives in essence not much more in­
formation than the patient's evaluation, because the doctor's opinion 
is based mainly on the patient's report. In our opinion, therefore, an 
IDA method as presented here is to be preferred to the traditional me­
thods of overall evaluation. Moreover, different physicians or nurse 
technicians dealing with one and the same patient, can calculate the 
individual's IDA at consecutive visits. 
Another solution to the problem of evaluating response might be to con­
sider the percentage of patients improving to an extent defined as cli­
nically significant. Figure 6 exemplifies this approach. From this we 
conclude that both drugs were capable of reducing the spinal pain in a 
considerable number of patients, and that DIF and PBZ were equally 
effective in the long run. Initially the percentage of patients with 
pain improvement by 2 points was considerably larger in the DIF group. 
When we looked at the percentage of patients with improvement of CL and 
LFI, PBZ was superior. Thus, although there were no baseline differ­
ences in CE and LFI, a substantial proportion of the patients on PBZ 
showed an increase in these parameters suggesting a greater influence 
on mobility than that achieved with DIF. Comparison of Figures 5 and 6 
shows that the differences between DIF and PBZ in terms of rapid onset 
of pronounced analgesia cannot be read from the usual statistical eva­
luation of data. 
Tender entheses and joints (Figure 3) existed in only a relatively 
small proportion of patients, and these patients continued to experi­
ence this discomfort. Although both thoracic pain and chest expansion 
improved, no change in vital capacity occurred (table III), probably 
due to diaphragmatic ventilatory compensation (19). In our opinion, 
these parameters (number of tender entheses and joints, and vital capa­
city) are therefore useless in trials of this kind; the same applies to 
the other parameters without significant change (finger-to-floor dis­
tance, occiput-to-wall distance). On the other hand, morning stiffness 
was a phenomenon present in a large percentage of patients and there­
fore could not possibly be excluded as a parameter. MS was reported by 
some patients lasting all day. For practical purposes we defined the 
upper limit of the MS value as θ hours to reduce the variation of this 
parameter (Table III). 
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Both drugs were tolerated rather well. Nevertheless 13 patients (68Go) 
on DIF and 11 (58%) on PBZ had an adverse clinical experience, usually 
transient and of mild intensity. About ¿tb™ of the patients in each 
group had an adverse experience associated with the gastrointestinal 
tract. In both groups three patients dropped out because of side 
effects (Table VII). Probably this relatively low incidence of drop-
outs due to side effects is not surprising, because most of the pa-
tients involved in the study had been using NSAIDs regularly for some 
time before the study. 
As already pointed out it is not easy to assess efficacy of drug treat-
ment in a chronic disorder like AS because its course is slowly pro-
gressive, with spontaneous remissions and exacerbations. Moreover, pa-
tients become more or less accustomed to their spinal pain, depending 
on the duration and seventy of the disease. 
Both drugs were capable of improving symptoms associated with AS, PBZ 
being somewhat more effective in increasing axial mobility. OIF could 
be used in the treatment of patients with AS in which pain, but not de-
creasing mobility, is the dominant symptom. Since treatment with PBZ 
can have serious haematological side effects (2) the use of other 
NSAIDs has to be stressed (20). In alphabetical order diclofinac, (21), 
flurbiprofen (22), indomethacin (3), naproxen (4,5) and Piroxicam (23) 
have proven to be good alternatives in the treatment of AS. Diflumsal, 
being another alternative, has the pharmacokinetic disadvantage of 
capacity-limited elimination (7). On the other hand, no serious side 
effects due to this mechanism have been reported. Response evaluation 
with the aid of an IDA may provide a useful tool in future trials and 
probably also in everyday practice; with regard to patient care one has 
to bear in mind that the IDA should never be the only aid used in judg-
ing an individual patient. 
85 
RLFERENCLS 
1. Boprsma, J.W. Retardation of ossification of the lumbar vertebral 
column in ankylosing spondylitis by means of phenylbutazone. Scand 
J Rheum, 1976, 5, 60-66. 
2. Vthovac, B. Phenylbutazon and related compounds. In: Meyler's side 
effects of drugs 10th ed. Editor: Dukes M.N.G. Amsterdam, Elsevier 
1984, 153-156. 
3. Calabro, J.J., Amante, C.M. Indomethacin m ankylosing 
spondylitis. Arthritis Rheufl, 1968, 11, 56-64. 
4. Hill, H.F.H., Hill, A.G.D. Ankylosing spondylitis: open long-term 
and double-blind crossover studies with naproxen. J Clin Pharmacol, 
1975, 15, 355-362. 
5. Ansell, B.M., Mayor, G., Liyanagp et al. A comparative study of 
butacote and naprosyn in ankylosing spondylitis. Ann Rheum Dis, 
197Θ, 37, 436-439. 
6. Godfrey, R.G., Calabro, J.J., Mills, D. et al. A double-blind 
crossover trial of aspirin, indomethacin and phenylbutazone in 
ankylosing spondylitis. Arthritis Rheum, 1972, 15, 110 (abstract). 
7. Brogden, R.N., Heel, R.C., Pakes, G.E. et al. Diflunisal: a review 
of its pharmacological properties and therapeutic use in pain and 
musculoskeletal strains and sprains and pain in osteoarthritis. 
Drugs,1980, 19, B4-106. 
B. Brooks, P.M., Dougan, M.A., Thomas, D., Hills, L.J., Smith, P.J. 
Naproxen and diflunisal in osteoarthritis. Rheumatol Rehab, 1982, 
21, 95-97. 
9. Huskisson, E.C., Dieppe, P.A., Scott, I., Jones, H. Diclofenac 
sodiun, diflunisal and naproxen: patient preferences for 
anti-inflammatory drugs in rheumatoid arthritis. Rheumatol Rehab, 
1982, 21, 238-242. 
10. Van Loenhout, J.W.A., van de Putte, L.B.Α., Gribnau, F.W.J., 
MacRae, K.D., Van Ginneken, C.A.M. Long-term clinical trial with 
naproxen sodium versus diflunisal in rheumatoid arthritis. M.D. 
thesis 1981, Nijmegen, pp 43-60. 
11. Ferraccioli, G., Spisni, Α., Ambarelli, К. Hypouricemic action of 
diflunisal in gouty patients: in vitro and in vivo studies. J 
Rheum, 1984, 11, 330-332. 
12. Bennet, P.H.J., Burch, T.A. Population studies of the rheumatic 
diseases. Amsterdam, Excerpta Medica Foundation 1968, pp 456-457. 
13. Steinbrocker, 0., Traeger, C.H., Batterman, R.C. Ara functional 
class. JAMA, 1949, 140, 659-665. 
14. Moll, J.H.M., Wright, V. An objective clinical study of chest 
expansion. Ann Rheum Dis, 1972, 31, 1-8. 
15. Van Adrichem, J.A.M., Van der Korst, J.К. Assessment of the 
flexibility of the lumbar spine. Scand J Rheum, 1973, 2, 87-91. 
16. Franssen M.J.A.M. et al. (chapter 4). 
17. Quanjer, Ph.H., Dalhuysen, Α., van Zomeren, В.С.Summary equations 
of reference values. In: Clin Resp Phys. Editor P.M. Quanjer, 1985, 
19, (suppl 5), 49. 
18. Forbes, J.Α., Beaver, W.T., White, E.H., White, R.W., Neilson, 
G.B., Shackleford, R.W. Diflunisal - a new oral analgesic with an 
unusually long term duration of action. JAMA, 1982, 24B, 2139 -
2142. 
19. Josenhans, W.T., Wang, CS., Josenhans, C , Woodbury, J.F.C. 
86 
Diaphragmatic c o n t r i b u t i o n to v e n t i l a t i o n in pat ients with 
ankylosing s p o n d y l i t i s . Resp, 1971, 28, 331-346. 
20. Wasner, C , B r i t t o n , M.C., Krames, R.G., Kaye, R.C., Bobrore, 
A.M., F r i e s , J.F. Non-steroidal ant i- inf lammatory agents i n 
rheumatoid a r t h r i t i s and ankylosing s p o n d y l i t i s . JAMA, 1981, 246, 
2168-2172. 
21. Rheinberger, K. Eff icacy and tolerance of d i c l o f i n a c and 
indomethacin in pat ients w i t h ankylosing s p o n d y l i t i s . 
Therapiewoche, 1976, 26, 2916-2920. 
22. Calm, Α., Grahame, R. Double-blind cross-over t r i a l of 
f l u r b i p r o f e n and phenylbutazone i n ankylosing s p o n d y l i t i s . Br Med 
J, 1974, 4, 496-499. 
23. Romberg, 0. Comparison of piroxicam wi th indomethacin in ankylosing 
s p o n d y l i t i s . A double-bl ind cross-over t r i a l . Am J Med, 1982, 73 
( s u p p l ) , 58-62. 
87 

Chapter 6 
LUNG FUNCTION IN PATIENTS WITH ANKYLOSING SPONDYLITIS. 
A STUDY ON THE INFLUENCE OF DISEASE ACTIVITY AND TREATMENT 
WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS 
MJAM Franssen, CLA van Herwaarden, LBA van de Putte, FWJ Gribnau 
submitted for publication 
SUMMARY 
Progressive ankylosis of the thoracic skeleton in ankylosing spondyl-
itis (AS) causes restrictive pulmonary function impairment character-
ized by a reduction in vital capacity (VC). After a wash-out period of 
2 weeks, 33 male patients with active AS were treated with either di-
flumsal or phenylbutazone according to a double-blind randomized 
design for 12 weeks, followed by an open extension period of 36 weeks. 
A spirometrie study was performed at baseline, week 12, and week 48. In 
the active phase of the disease a correlation was found between VC and 
chest expansion, whereas neither of these parameters was related to the 
thoracic pain and overall disease activity. We also found that the VC 
correlated with the lumbar flexion index, but not with the ESR. Al-
though all clinical efficacy parameters showed an improvement during 
treatment with both drugs studied, no change in VC was found; not even 
in the patient group with the most restricted ventilatory function im-
pairment. We therefore conclude that the VC is neither an important nor 
an appropriate parameter in monitoring the effectiveness of drug thera-
py in AS. 
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INTRODUCTION 
Ankylosing spondylitis is a rheumatic disease characterized by inflam-
mation of the axial skeleton, often leading to ankylosis. The thoracic 
cage is frequently involved in the disease process: besides the thorac-
ic vertebral column, the costovertebral, costochondral and costosternal 
joints may be involved, leading to limitation of chest expansion (1). 
Studies in the past have indicated that involvement of the thorax is 
often associated with a restrictive type of lung function impairment, 
characterized by a decreased vital capacity mainly at the cost of the 
inspiratory reserve volume (1,2,3,4,5). No systematic study has so far 
been made of the influence of the seventy and course of the inflamma-
tory process on pulmonary function impairment. In addition, only scanty 
data are available on whether or not treatment with non-steroidal 
anti-inflammatory drugs (NSAIDs) influences pulmonary function impair-
ment. In the present study we present data obtained during a clinical 
trial in patients with ankylosing spondylitis treated with NSAIDs. Lung 
function during an active phase of the disease was correlated with 
standard disease activity parameters. In addition, we studied the in-
fluence of long-term treatment with NSAIDs on both lung function and 
standard disease activity parameters. 
PATIE.NTS AND METHODS 
Included in the study were 33 patients, all men, mean age 36.6 years 
(range from 19 to 54 yrs), with definite ankylosing spondylitis (6). 
All patients had a flare-up of disease activity after stopping NSAIDs 
for two weeks. A flare-up was defined as a clinical worsening of the 
patient's condition in which pain was an essential component and had 
reached a degree of seventy requiring therapy. This was usually accom-
panied by increased stiffness. The patients were not allowed to use 
systemic corticosteroids or NSAIDs other than those prescribed (see 
below). Excluded from the study were patients with other lung disorders 
or rheumatic diseases. After a wash-out period of 2 weeks, patients 
were treated for 12 weeks with either diflumsal 500 mg twice daily or 
9] 
phenylbutazone 200 mg twice daily according to a double-blind 
randomized design. They were seen every two weeks at our out-patient 
department by one investigator (MF). This period was followed by an 
open extension period of 36 weeks, in which the patients were seen 
every 4 weeks. Of the parameters studied, the following were relevant 
to the present report: pain in the thoracic region and spine scored by 
the patient using a 5-point scale ranging from 0 (no pain) to 4 (very 
severe pain); overall disease activity scored by the investigator ac-
cording to a 4-point scale ranging from 0 (no signs or symptoms) to 3 
(overwhelming symptoms); lumbar flexion index (7) and chest expansion 
(8) (taking the maximum of two measurements). Laboratory parameters in-
cluded an ESR according to Westergren, haemoglobin, white blood cell 
and platelet counts. During the study X-rays of the vertebral column, 
sacro-iliac joints and chest were made in all cases. The radiographic 
findings of the thoracic vertebral column were graded according to 
Rogan et al (2). A spirometrie examination (Pulmonet III Gould Godard) 
was performed at weeks 0, 12 and 48. Vital capacity (VC) and forced 
expiratory volume 1 second (FEV·); highest of two observations) were 
determined. Total lung capacity (TLC) and functional residual capacity 
(FRC) were measured using the helium dilution method (closed-circuit 
helium technique, Godard). Normal values were calculated from age- and 
height-derived regression equations (9). Since a flexion deformity due 
to ankylosing spondylitis may reduce the height of the patient, we used 
the arm span instead. According to the vital capacity the patients were 
divided into two groups: those with normal and those with restricted 
lung function. Restricted lung function was defined as a vital capacity 
less than the mean normal value minus two times the standard deviation 
(9). In addition we studied pulmonary function in 10 patients with an-
kylosing spondylitis who had end-stage disease with total ankylosis of 
the vertebral column. All patients gave their informed consent. The 
design of the study was approved by the Ethics Committee of the Medical 
Faculty of the University of Nijmegen. 
The results are expressed as mean ± SD. Statistical analysis was car-
ried out using Student's t test for (uri)paired observations. Correla-
tions among parameters were assessed using parametric correlation 
methods. 
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RESULTS 
The clinical characteristics of the 33 patients after the drug-free 
period, are shown in Table I. None of the patients had obstructive lung 
function impairment. 
Table I. PATILNT CHARACTERISTICS (at baseline, n=33) 
Parameter 
Age 
Weight 
H e i g h t 
Arm span 
D u r a t i o n 
Chest exρ 
Lumbar f l 
ESR 
Hgb 
TLC 
VC 
RV 
FEV-i/VC 
o f c o m p l a i n t s 
a n s i o n 
ex i o n index 
Mean 
36.6 
72.4 
172 
1B1 
9 . 0 
3.5 
3 . 8 
23 
8.8 
B3 
84 
82 
79 
SD 
8.7 
11.3 
7 
8 
5.8 
2.0 
2.1 
18 
0.7 
11 
14 
22 
6 
Range 
20-54 
54-97 
160-184 
167-199 
0 . 5 - 2 1 
1-10 
1 . 0 - 7 . 5 
2-63 
7 . 4 - 1 1 . 0 
65-117 
61-116 
44-137 
68-94 
% 
% 
U n i t s 
y r s 
kg 
cm 
cm 
y r s 
cm 
cm 
mm/h 
mmol/1 
p r e d i c t e d 
p r e d i c t e d 
p r e d i c t e d 
o f VC 
Next, we studied the possible relationship between various thoracic 
disease-associated parameters and other clinical and laboratory para­
meters in the active phase of the disease (Table II). There was a sig­
nificant correlation between vital capacity and chest expansion, but 
not between vital capacity and thoracic pain, nor between chest expan­
sion and thoracic pain. Other significant correlations included a cor­
relation between thoracic pain and disease activity, between chest ex­
pansion and duration of complaints and lumbar flexion index, and be­
tween vital capacity and lumbar flexion index (Table II). When the 33 
patients were divided according to vital capacity, we obtained a group 
of 19 patients with normal and a second group of 14 patients with re­
duced vital capacity. Of the clinical parameters studied (Table III), 
only chest expansion and lumbar flexion index differed between these 
groups. The laboratory paraneters did not differ between the two 
groups; lung function parameters showed differences in TLC and FEV-|/VC 
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to 
Table II. CORRELATION BETWEEN RELEVANT SYMPTOMS, SIGNS AND LABORATORY VALUES AT BASELINE (n=33) 
duration of thoracic disease chest lumbar ESR 
complaints pain activity expansion flexion index 
Thoracic pain 0.04 X 0.47** -0.21 -0.04 0.08 
Chest expansion -0.38* -0.Z1 -0.21 X 0.56*** -0.17 
Vital capacity -0.23 -0.11 -0.17 0.63*** 0.49** -0.29 
* p<0.05 
* * p<0.01 
* * * p<0.001 
Table III. DIFFERENCES BETWEEN RESTRICTEU-1" AND NON-RESTRICTED GROUP AT 
BASELINE 
Parameters 
D u r a t i o n o f c o m p l a i n t s ( y r s ) 
Thoracic p a i n ( s c o r e ) 
Disease a c t i v i t y ( s c o r e ) 
Chest expansion (cm) 
Lumbar f l e x i o n index(cm) 
ESR (mm/h) 
Hgb (mmol/1) 
TLC % 
RV % 
FEVi/VC % 
VC % 
RESTRICTED 
(π=14) 
1 0 . 0 ± 5 . 2 
1.6+1.1 
1.8±0.7 
2.3±0.9 
2 . 7 ± 1 . 5 
30+18 
8 . 7 + 1 . 0 
74 ±8 
87±25 
83 ±7 
71 ±5 
NON-RESTRICTED 
(η=19) 
8 . 3 ± 6 . 2 
1.2±1.1 
1.7±0.7 
4 . 3 ± 0 . 7 
4 . 6 ± 2 . 2 
22+18 
8 . 8 + 0 . 5 
89±10 
78±19 
77+4 
94 ±9 
ρχ 
N.S. 
N.S. 
N.S. 
ρ<0.01 
ρ<0.01 
N.S. 
N.S. 
р<0.001 
N.S. 
ρ<0.01 
-
+ restricted lung function defined as VC<79?ó of the predicted value (9) 
χ p-values obtained with unpaired Student's t test. 
Table IV. VALUES (mean ± SD) OF CLINICAL AND LABORATORY MEASUREMENTS AT 
BASELINE AND AFTER 12 RESP. 48 WEEKS OF TREATMENT WITH NSAIDs 
Parameter 
Thorac ic p a i n 
Disease a c t i v i t y 
Chest expansion 
Lumbal f l e x i o n i n 
ESR 
V i t a l c a p a c i t y 
idex 
B a s e l i n e 
(n=33) 
1.4+1.1 
1.7±0.7 
3 . 5 + 2 . 0 
3 . 8 + 2 . 1 
25+18 
84±14 
Week 12 
(n=2B) 
0 . 7 ± 1 . 0 
1.0±0.6 
4 . 1 + 1 . 9 
4 . 5 + 2 . 1 
17±6 
84+14 
p x 
»** 
*** 
** 
** 
** 
N.S. 
Week 48 
(n=Z5) 
0 . 9 + 1 . 2 
0 . 9 + 0 . 8 
4 . 5 ± 2 . 3 
4 . 5 ± 2 . 0 
19±19 
84+16 
P x 
* 
*** 
x·** 
** 
N.S. 
N.S. 
* p<0.05 
** p<0.01 
*** p<0.001 
χ p-values obtained with paired Student's t test 
(Table III). The residual volume showed no difference. The influence of 
NSAIDs on pulmonary function test and standard disease activity para­
meters was studied using either phenylbutazone or diflunisal as active 
drugs. Since there were no consistent differences in the effects of 
these two drugs, the two treatment groups were taken together (Table 
IV). Although there was long-lasting significant improvement in thorac­
ic pain, chest expansion, disease activity and lumbar flexion index, 
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vital capacity values did not change. Of the laboratory paraneters, the 
ESR decreased significantly after 12 weeks but not after 48 weeks. 
Looking separately at the groups with normal and with restrictive lung 
function respectively, we still found no changes in lung function para­
meters during NSAID treatment (Figure 1). 
% 
1 0 0 n 
8 0 
60H 
4 0 
20H 
0 
VC 
33 
weekO 
vU 19 
12 
18 
48 
15 
week 0 
14 
12 48 
J ^ JL 
10 10 
FEVi/VC 
D 
JL 
10 =N 
normal non-restricted restricted ankylosis 
Figure 1. Pulmonary function parameters TLC, VC (standard deviation), 
RV and FEV-i/VC at baseline and during treatment with NSAIOs 
in the non-restricted patients (n=19), the restricted pa­
tients (n=14) and the patients with end-stage disease and 
ankylosis (n=10) 
Radiological examination of the thoracic vertebral column showed that, 
in the restrictive group, 4 (30?£) of the patients had no or minor 
changes and 10 (70?ί) had advanced changes and ankylosis, while in the 
non-restricted group these figures were 14 (75%) and 5 (25%), respec­
tively (Figure 2). The mean VC values differ significantly (p<0.05) be­
tween radiological grade I + II (89 +15% of predicted) and grade III + 
IV (78 +_ 11% of predicted). None of the patients in either group had an 
abnormal chest X-ray, i.e. no changes in the upper lobes were ob­
served. The 10 patients with end-stage disease and a mean chest expan­
sion of 1.8 ± 0.6 cm showed a reduced VC of 65 ±11% of predicted with 
an RV 84 ± 33% of predicted value (Figure 1). 
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120 n 
100 
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Figure 2. Radiological gradings of the thoracic vertebral column (2), 
and vital capacity values at baseline 
DISCUSSION 
The most important and consistent finding in pulmonary function studies 
in ankylosing spondylitis (AS) is reduction of the vital capacity (VC) 
(2,3,4). Our data indicate that there is a correlation between chest 
expansion (CE), a measure of the degree of stiffness of the thoracic 
cage, and VC. However, CE is much more impaired than would be expected 
from VC values. This discrepancy may be related to the fact that the 
function of the diaphragm limits the impairment of the VC (10,11). An-
other interesting finding in this study was that, during drug therapy, 
no changes in VC were found, although thoracic pain decreased and CE 
increased. Regular measurements of VC are therefore unsuitable for mo-
nitoring the effectiveness of drug therapy in ankylosing spondylitis 
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over a limited time span. 
Our data on lung function impairment in AS confirm reports of others 
(2,12,13,14) who demonstrated reduction of the VC mainly at the expense 
of the inspiratory reserve volume, and also a decrease of total lung 
capacity (TLC) and a normal or slightly reduced residual volume (RV). 
However, several other investigators found an increased RV in the pres-
ence of a normal (3,4) or reduced (1,5,11) TLC. There may be several 
reasons for this controversy: different methods to calculate normal 
lung function values (15,16,17); whether or not corrections were made 
for the reduced height caused by flexion deformity of the spine; and 
differences in patient selection. We, and others (1,13) found no signs 
of obstructive lung function impairment; and in addition we found that 
the forced expiratory volume 1 second made up a greater part of the VC, 
as would be expected in a restrictive lung disease. 
Previous investigators (2,18) have indicated a correlation between VC 
reduction and seventy of the disease as measured by the extent of ra-
diological changes. In our study comparing VC reduction with clinical 
parameters, a correlation was found between the former and both lumbar 
flexion index and chest expansion (10) . Especially in the restricted 
group there was a marked discrepancy between VC reduction (71 ± 5% of 
predicted) (9) and CE limitation (31 ± 8?o of predicted) (8) at base-
line. The reduction in VC is limited because the diaphragmatic function 
is unimpaired and compensates to a certain extent (10). This means that 
assessment of the chest expansion in AS has only limited predictive 
value regarding the degree of restrictive pulmonary function impair-
ment. The correlation we found between VC and LFI is in agreement with 
data reported by Wilkinson and Bywaters (19). This may be explained by 
the fact that impairments of both CE and LFI are early manifestations 
of AS (1,12,19). 
It is known that the ESR in general is not a suitable measurement to 
assess disease activity in AS, at least in the absence of peripheral 
arthritis (20). Because in the majority of our patients the illness was 
mainly limited to the axial skeleton, a relation between ESR and other 
parameters of thoracic cage impairment was not to be expected and in-
deed was not found. 
In our study 14 of 33 patients showed restrictive pulmonary function 
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impairment (Table III). In these patients the disease was not of 
longer duration nor did they have more complaints than the 19 non-res­
tricted patients. Besides, 30% of the restricted patients showed no or 
only minor X-ray changes in the thoracic vertebral column, while 250ί of 
the non-restricted patients showed advanced changes and ankylosis 
(Figure 2). In view of these findings we concluded that there is an 
individual difference m the course regarding extension and progression 
of this disease, and furthermore that the presence of extensive ankylo­
sis of the vertebral column is not necessarily associated with restric­
tive pulmonary function impairment. 
Since it is important to consider to what extent restrictive pulmonary 
function impairment evolves, we studied the lung function of IG pa­
tients with end-stage ankylosing spondylitis. The mean chest expansion 
in this group was 1.8 ± 0.6 cm. As shown in the Figure 1 the progres­
sion m VC reduction is limited (in our observations a VC reduction of 
65 ± 11°i> of predicted (9)). This confirms the findings of others (3) 
and supports the clinical observation that AS patients rarely show 
signs of respiratory insufficiency. 
Although both drugs studied caused improvement after 12 weeks, reflect­
ed by a decline in thoracic pain and overall disease activity, no 
changes in VC were recorded (Table IV). Nevertheless, the CE and LFI 
showed an increase and the ESR a decrease. In the 36-week open exten­
sion period, these effects on clinical parameters remained present, but 
once again the VC did not change, either in the restrictive or in the 
non-restrictive group (Figure 1). 
Although there seems to be a correlation between CE and VC at baseline, 
none of the patients showed VC improvement, while the CE increased. 
Other investigators (10), who studied the effect of physical therapy, 
also found an increase in CE without a change in VC. They stated that 
VC measurements cannot detect changes in respiratory muscle function 
and the effect of physical therapy in AS. From these and our observa­
tions we conclude that the VC is neither an important nor an appropri­
ate parameter in monitoring the effectiveness of drug therapy in AS, 
which is in contrast with the suggestions made by Renzetti et al (18). 
A possible explanation of these findings may be that VC reduction indi­
cates an irreversible change in pulmonary function due to stiffening of 
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the thoracic cage, which cannot be compensated by increased diaphragma-
tic excursions. VC reduction is not related to the activity of AS, but 
mainly an expression of the extent to which the thoracic wall, es-
pecially the costovertebral and costosternal joints, are affected by 
the disease process. 
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SUMMARY 
We investigated possible association between serum IgA, IgM and IgG and 
disease activity in a longitudinal study of 4Θ weeks duration in 38 
male patients with active ankylosing spondylitis receiving regular 
treatment with either phenylbutazone or diflumsal. Throughout the 
study serun IgA levels correlated most frequently with chest expansion 
and lumbar flexion index whereas patients with extensive radiological 
changes also had highest serum IgA levels. Likewise, changes in IgA, 
but not in IgM and IgG, correlated with changes in a composite index of 
disease activity (IDA). Changes in ESR showed a similar correlation 
with changes in IDA, whereas changes in serum IgA and ESR showed no 
consistent correlation, suggesting that both parameters reflect 
different aspects of disease. Serum IgA, ESR, and IDA values all de­
creased during regular drug treatment, suggesting a disease modifying 
effect of the NSAIDs studied. Regular measurement of serum IgA may be 
useful in the assessment of disease activity of ankylosing spondylitis. 
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INTRODUCTION 
Two observations have recently pointed to the possible importance of 
serum IgA levels in ankylosing spondylitis (AS). Firstly, IgA serum 
levels have been found dominantly raised as compared with other immuno­
globulins in AS (1,2,3,4). Secondly, disease activity in AS has been 
associated with the presence of Klebsiella pneumoniae in the faeces of 
patients with AS (5,6,7), although other studies have been unable to 
confirm these data (8,9,10). Since humoral immune responses in the gut 
are mainly of the IgA type (11), several authors looked for and in fact 
found an association between serum IgA levels and disease activity in 
AS (2,3,12,13). 
If IgA serum levels would indeed be a parameter for disease activity in 
AS, this would be helpful because assessment of activity by clinical 
parameters is problematic in this disease, especially when peripheral 
arthritis is absent. Longitudinal studies on IgA serum levels and dis­
ease activity in AS have not so far been carried out. 
The aim of the present study was to investigate in a prospective longi­
tudinal way the possible relationship between serum IgA levels and cli­
nical disease activity in AS. This study was part of a clinical trial 
comparing the efficacy of two NSAIDs, phenylbutazone and diflunisal, 
against disease activity in AS. In addition we studied possible corre­
lations between serum IgA levels and radiological features of the dis­
ease. 
PATIENTS AND METHODS 
The present study was part of a clinical trial in male patients with 
ankylosing spondylitis, comparing treatment with phenylbutazone versus 
diflunisal, as reported elsewhere (14). The study comprised 3Θ patients 
aged between 18 and 55 years with a diagnosis of ankylosing spondylitis 
according to the New York criteria (15), confirmed by two or more of 
the following symptoms: back pain, morning stiffness and progressive 
limitation of movement. Patients were admitted only when they showed a 
flare-up during or after a drug withdrawal period of maximally 14 
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days. A flare-up was defined as a worbening of the patient's condition 
in which pain and stiffness was an essential component, requiring 
treatment. After this wash-out period patients were randomly allocated 
to receive either diflumsal (500 mg twice daily) or phenylbutazone 
(200 mg twice daily), resulting in two treatment groups of 19 patients 
each. The study covered a 12-week double-blind period followed by an 
open extension period up to week 40. Nine patients dropped out: three 
in each treatment group due to side effects and one in each group due 
to lack of efficacy. Another one was lost to follow-up. Of the parame-
ters studied, the following are relevant to the present report: dominai 
spinal pain (DSP; cervical, thoracic or lumbar sacroiliac), scored by 
the patient using a 5-point scale ranging from 0 (no pain) to 4 (very 
severe pain), morning stiffness (MS) in minutes since arising, chest 
expansion (CE) (16) and lumbar flexion index (LFI) (17) assessed by the 
investigator by taking the maximum of two measurements. 
Laboratory parameters included an ESR according to Westergren and 
serum immunoglobulins as assessed by the radial immunodiffusion method 
of Mancini using standard commercially obtained immuno-diffusion plates 
and standards (Behringer Werke, Marburg, West Germany) (18,19). All 
measurements were done at baseline and at weeks 12, 24, 36 and 48 
thereafter. In addition to the individual parameters we used an index 
of disease activity (IDA) to evaluate the response. The four components 
of this IDA and its gradings are shown in Table I. The individual's 
mean of the four graded parameters was used as the IDA for that pa-
tient, being minimally 0 and maximally 4. During the study an X-ray of 
the vertebral column, the sacroiliac joints and the chest was made. The 
Table I. GRADING OF DSP, MS, CE AND LFI ACCORDING TO INCREASING 
SEVERITY 
0 1 2 3 4 
DSP (0-4) 0 1 2 3 4 
MS min <10 10-30 31-60 61-120 >120 
CE cm > 7 6.9-5.0 4.9-3.5 3.4-2.0 < 2.0 
LFI cm > 7 6.9-5.0 4.9-3.5 3.4-2.0 < 2.0 
The IDA of an individual patient is calculated as the mean of his score 
for the four respective components 
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radiographic findings were graded according to Rogan et al (20), i.e. 
grade 1: changes confined to sacroiliac joints; grade 2: early changes 
in the spane as well as in sacroiliac joints; grade 3: well-marked 
changes in the thoracic and lumbar spine with some evidence of anky-
losis, as well as marked changes in sacroiliac joints; grade 4: gross 
changes in sacroiliac joints and thoracic and lumbar spine. For com-
parison of immunoglobulin and ESR values we used baseline data from 14 
male patients with rheumatoid arthritis (RA), obtained during a single 
blind study comparing auranofin and aurothioglucose (21). Moreover, im-
munoglobulin levels of 40 healthy male blood donors, mean age 37 ± 12 
years, were used as normal controls. Their mean serum immunoglobulin 
concentrations plus once the standard deviation were considered as nor-
mal values. 
Mean changes in immunoglobulin levels compared to baseline were 
assessed using the paired Student t-test. Correlations among clinical 
and laboratory parameters were assessed using parametric correlation 
methods. 
RESULTS 
Serum immunoglobulin levels in active ankylosing spondylitis. 
Table II shows mean serum immunoglobulin levels in the active phase of 
AS, i.e. at baseline (week 0). Mean serum IgA levels are raised in both 
AS and RA, showing no significant difference. Serum IgM levels are 
higher in male patients with AS than in those with RA. In contrast, ESR 
values are significantly (p<0.001) higher in male RA (54 ± 32 mm/h) 
than in male AS patients (26 ± 18 mm/h). Looking at the dominantly 
raised serum immunoglobulin level, we found that IgA was the dominantly 
increased serum immunoglobulin in 38% of the AS patients. IgG and IgM 
were dominantly raised in 19% and 5% of the patients with AS respec-
tively. Thirty-eight percent of the patients with AS had no serum immu-
noglobulin increase at all. 
Disease activity and serum immunoglobulin levels. 
Table III shows correlations between serum immunoglobulin levels, ESR, 
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Table II. IMMUNOGLOBULIN LEVELS (mean ± SD) IN HEALTHY CONTROLS (C), ANKYLOSING SPONDYLITIS (AS) AND 
RHEUMATOID ARTHRITIS (RA) 
male С (n=40) male AS (n=38) male RA (n=14) AS vs С RA vs С AS vs RA 
IgA (g/1) 2.17 ± 0.94 3.30 ± 1.53 3.73 ± 1.15 p<0.001 p<0.001 NS 
IgM (g/1) 1.46 ± 0.85 1.85 ± 0.64 1.31 ± 0.56 p<0.05 NS p<0.01 
IgG (g/1) 11.06 ± 2.55 14.42 ± 3.63 16.80 ± 5.25 p<0.001 p<0.001 0.05<p<0.1 
NS = not s i g n i f i c a n t 
Table III. CORRELATIONS BETWEEN CLINICAL AND LABORATORY PARAMETERS 
THROUGHOUT THE STUDY 
week 
0 
n=38 
12 
n=32 
24 
n=29 
36 
n=29 
48 
n=29 
• 
** 
*** 
parameter 
IgA 
IgM 
IgG 
ESR 
IgA 
IgM 
IgG 
ESR 
IgA 
IgM 
IgG 
ESR 
IgA 
IgM 
IgG 
ESR 
IgA 
IgM 
IgG 
ESR 
p<0.05 
p<0.01 
p<0.001 
DSP 
- 0 . 0 5 
- 0 . 0 2 
- 0 . 0 8 
0.16 
- 0 . 0 7 
- 0 . 1 3 
- 0 . 3 1 
0.26 
- 0 . 0 2 
0.13 
- 0 . 2 0 
- 0 . 0 1 
- 0 . 1 2 
0.01 
- 0 . 2 6 
- 0 . 0 6 
0.15 
0.36 
0.10 
0.0Θ 
MS 
0.05 
0 . 3 7 * 
0.Ü7 
- 0 . 1 5 
- 0 . 2 9 
0.11 
- 0 . 2 9 
- 0 . 2 0 
0.08 
0.08 
- 0 . 2 8 
- 0 . 2 9 
- 0 . 3 2 
0.02 
- 0 . 2 5 
- 0 . 3 0 
- 0 . 3 3 
- 0 . 0 7 
- 0 . 3 8 
- 0 . 2 1 
CE 
- 0 . 2 8 
- 0 . 3 2 
- 0 . 3 3 * 
- 0 . 1 4 
- 0 . 3 4 * 
- 0 . 2 4 
- 0 . 3 0 
- 0 . 1 6 
- 0 . 4 7 * * 
- 0 . 2 6 
- 0 . 3 1 
- 0 . 2 4 
- 0 . 5 1 * * 
- 0 . 1 1 
- 0 . 3 8 * 
- 0 . 3 9 * 
- 0 . 4 5 * 
- 0 . 1 3 
- 0 . 2 4 
- 0 . 2 7 
LEI 
- 0 . 4 7 * * 
- 0 . 3 1 
- 0 . 4 4 * * 
- 0 . 4 3 * * 
- 0 . 5 3 * * 
- 0 . 3 8 * 
- 0 . 4 7 * * 
- 0 . 2 8 
- 0 . 6 1 * * * 
- 0 . 4 0 * 
- 0 . 4 7 * 
- 0 . 4 5 * 
- 0 . 4 9 * * 
- 0 . 5 1 * * 
- 0 . 3 9 * 
- 0 . 4 3 * 
- 0 . 4 8 * * 
- 0 . 3 3 
- 0 . 3 4 
- 0 . 4 7 * * 
IDA 
0.31 
0 . 4 4 * * 
0.28 
0 . 3 4 * 
0 .28 
0.28 
0.05 
0.20 
0.34 
0 .40 * 
0.08 
0.13 
0.25 
0.21 
0.06 
0.15 
0.25 
0.27 
0.08 
0.20 
ESR 
0 . 6 5 * * * 
0.01 
0 . 3 9 * 
X 
0 . 5 0 * * 
- 0 . 0 3 
0 .39* 
X 
0 . 7 0 * * * 
0 .09 
0 . 5 9 * * * 
X 
0 . 6 1 * * * 
0.08 
0 . 5 9 * * * 
X 
0 . 7 2 * * * 
0 .09 
0 . 6 3 * * * 
X 
and clinical parameters. Laboratory parameters frequently correlated 
with the objective clinical parameters, i.e. chest expansion and lumbar 
flexion index. Most correlations were found for IgA (9 times) , followed 
by IgG (6 times), ESR (5 times) and IgM (3 times). No consistent corre-
lations were found between laboratory parameters and dominant spinal 
pain, morning stiffness and the index of disease activity. Table III 
also shows a consistent and close correlation between ESR and IgA and, 
to a lesser extent, IgG. 
Next we studied changes in laboratory parameters and clinical parame-
ters during treatment. Since there were no consistent differences 
between the effects of both treatments, the two groups were taken 
together. Figure 1 shows mean serum immunoglobulin levels throughout 
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Figure 1. Mean immunoglobulin levels during the study for all patients 
completing the trial, and separately for those with a normal 
and a raised IgA serum level, respectively 
(* p<0.05, ** p<0.01, *** p<0.001) 
the study, indicating the most significant changes in IgA at week 24 
and thereafter. Table IV shows correlations between changes during 
treatment. This table indicates that, so far as immunoglobulins and 
index of disease activity are concerned, most correlations are found 
for IgA, followed by IgM. Correlations of ESR with index of disease 
activity were comparable with those of IgA, although correlations 
between IgA and ESR became significant only after 36 and 48 weeks. Of 
the individual IDA components only lumbar flexion index changes showed 
correlations with immunoglobulin changes, most frequently with IgA: two 
times significant and two times close to significance (0.05<p<0.1). 
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Table IV. CORRELATIONS OF CHANGES AS COMPARED WITH BASELINE BETWEEN 
PARAMETERS DURING THE STUDY 
week parameter 
AWO-W12 IgA 
n=32 IgM 
IgG 
ESR 
AWO-W24 IgA 
n=29 IgM 
IgG 
ESR 
AW0-W36 IgA 
n=29 IgM 
IgG 
ESR 
AW0-W48 IgA 
n=29 IgM 
IgG 
ESR 
+ 0.05<p<0.01 
* p<0.05 
** p<0.01 
DSP 
0.11 
0.1Θ 
0.20 
0 . 3 9 * 
0.24 
0.31 
0.14 
0.30 
0.29 
0.05 
0.17 
0 . 3 9 * 
- 0 . 0 3 
0.06 
0.02 
0.07 
MS 
0.25 
0.28 
0.17 
0.23 
0.35+ 
0.1B 
0.14 
0.28 
0.32+ 
0.00 
0.21 
0.20 
0.12 
- 0 . 1 4 
0.13 
0.05 
CE 
0.05 
- 0 . 2 3 
- 0 . 0 3 
- 0 . 1 3 
0.01 
- 0 . 1 2 
- 0 . 1 4 
- 0 . 0 3 
- 0 . 0 0 
0.22 
0.06 
- 0 . 0 7 
- 0 . 1 1 
- 0 . 0 9 
- 0 . 0 7 
0.02 
LFI 
- 0 . 3 3 + 
- 0 . 4 3 * 
- 0 . 2 5 
- 0 . 0 3 
- 0 . 4 6 * 
- 0 . 1 0 
- 0 . 0 5 
- 0 . 1 6 
- 0 . 3 7 * 
- 0 . 0 8 
- 0 . 0 1 
- 0 . 1 5 
- 0 . 3 3 + 
- 0 . 2 8 
- 0 . 1 2 
- 0 . 0 5 
IDA 
0 . 3 8 * 
0 . 3 6 * 
0.18 
0 . 4 2 * 
0 . 5 4 * * 
0 . 3 7 * 
0.28 
0 . 5 6 * * 
0 . 4 1 * 
- 0 . 1 2 
0.06 
0 . 3 9 * 
0.34+ 
0.14 
0.29 
0.17 
ESR 
0.28 
0.10 
0.10 
X 
0.13 
0.06 
0.09 
X 
0 . 4 5 * 
0.16 
0.07 
X 
0 . 5 8 * * 
0.04 
0.02 
X 
Relation between serum IqA levels at baseline and radiological fea­
tures. 
Since radiological features at least partly reflect disease activity, 
we studied serum immunoglobulin levels in the various radiological ca­
tegories. As shown in figure 2, radiological grades 2, 3 and 4 differ 
significantly from grade 1 in mean serum IgA level (p<0.01). No such 
differences were found for IgM and IgG. 
DISCUSSION 
This study presents evidence that serum IgA levels, more than those of 
IgM and IgG, are associated with disease activity in ankylosing spon­
dylitis. Firstly, absolute values of serum IgA were found to correlate 
with the objective disease parameters lumbar flexion index and chest 
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Figure 2. Radiological gradings of the axial skeleton (20), and serum 
IgA levels at baseline 
expansion throughout the study. Secondly, and probably most important, 
changes in serum IgA correlated with changes of disease activity ex­
pressed in index of disease activity (IDA) values. Finally, mean serum 
IgA levels increased as the radiological changes became more severe. It 
should be stressed that these data were obtained in, and therefore only 
apply to the group studied, i.e. male patients with ankylosing spondyl­
itis, without peripheral arthritis, who showed a flare-up of pain and 
stiffness after a drug-free period. 
Serum immunoglobulin levels have been found raised in ankylosing spon­
dylitis by several authors, the most significant rise being that in 
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serum IgA (1,2,3,4). A few studies have indicated that serum IgA levels 
may be related to disease activity (2,3,12,13). However, no longitudi-
nal studies have been done so far. The present study is the first to 
show that changes in serum IgA levels parallel changes in disease acti-
vity of ankylosing spondylitis. Similar changes were not found for the 
other immunoglobulins studied. 
Evidence that serum IgA levels are somehow related to disease activity 
in ankylosing spondylitis may be important in several respects. A num-
ber of studies have indicated that other HLA-B27 related disorders, 
i.e. Reiter's syndrome and reactive arthritis, can be precipitated by 
an enteric infection (22,23,24). Since IgA is the predominant immuno-
globulin produced by the gastrointestinal mucosa (11), association of 
IgA serum levels and disease activity as found m the present study may 
point to the localisation of a causative pathogen in the gut (2,6,7). 
In fact Fbnnger et al (5) have reported evidence of the association 
between the presence of Klebsiella pneumoniae in the faeces of patients 
with ankylosing spondylitis and active disease. Other groups, however, 
have been unable to confirm these data (8,9,10). Another interesting 
observation was that serum IgA levels decreased during regular treat-
ment with NSAIDs. Since changes in serum IgA were parallelled by 
changes in disease activity, these observations suggest that NSAIDs may 
have a disease modifying effect in ankylosing spondylitis. Compatible 
with this view would be the observation in our study that there was 
also a decrease in ESR during treatment. In this respect it is in-
teresting that one previous study presents evidence of delayed ossifi-
cation of the lumbal vertebral column in ankylosing spondylitis due to 
phenylbutazone treatment (25). 
Of practical importance is that the present data justify the use of 
serum IgA levels as another parameter of disease activity. At present 
ESR and acute phase proteins such as CRP are most frequently used as 
laboratory parameters of disease activity (2,26). However, the value of 
the latter parameters has been questioned in AS (3,27,28). In any case 
the serum IgA levels may give valuable additional information, as 
suggested by our finding that, especially in the earlier part of the 
trial, there was no correlation between changes in ESR and those in IgA 
serum levels. 
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In our group of patients the mean serum IgA levels were related to the 
extent of radiological abnormalities. The latter, at least partly, re-
flects disease seventy, although duration of the disease admittedly 
also plays a part. If, as suggested by our data, serum IgA levels re-
flect disease activity, this would mean that patients with persistent 
highly raised serum IgA levels are most at risk to develop extensive 
axial inflammation, and therefore ankylosis and flexion deformity. This 
group should be considered for regular treatment with NSAIDs, especial-
ly when this type of treatment has a disease-modifying effect, as our 
data suggest. 
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Chapter θ 
SUMMARY AND CONCLUSIONS 
SUMMARY AND CONCLUSIONS 
Ankylosing spondylitis is an inflammatory disease of unknown etiology 
affecting mainly the axial skeleton and root joints. Usually it pro­
gresses with fluctuating course and in general has a favourable prog­
nosis regarding validity. Patients suffer from pain and stiffness, 
worse at night and the early morning, and show a decreasing mobility of 
the spinal column and chest. 
As no curative agent for this disease has been found, effective manage­
ment depends on the diagnosis being made as early as possible and 
application of various therapeutic measures, including daily exer­
cises, physical therapy and drug treatment with NSAIDs. By relieving 
pain and stiffness these agents permit preservation of a functional 
posture and at least m part maintenance of mobility. So treatment can 
indeed improve the patient's general condition and keep the development 
of a flexion deformity to a minimum. Many patients are able to continue 
a reasonably normal daily and occupational live. 
In chronic rheumatic diseases like ankylosing spondylitis, double-blind 
randomized controlled clinical trials provide a reliable basis for eva­
luating the efficacy and safety of treatment with NSAIDs. There are two 
main reasons for doing clinical trials in ankylosing spondylitis: on 
the one hand the fluctuating course with spontaneous remissions and 
exacerbations, and on the other hand the nature of the treatment, up to 
now mainly symptomatic and not curative. Clinical trials can also be 
used to assess the value of certain efficacy parameters and other, 
non-drug related aspects of the disease itself and patient management. 
The aim of this study was to investigate the efficacy and tolerance of 
diflumsal, a salicylic acid derivative, in ankylosing spondylitis by 
using phenylbutazone, a pyrazolon derivative, as a reference drug. 
Several comparative studies in the past have shown that phenylbutazone 
is a useful NSAID in the treatment of ankylosing spondylitis. Upon 
chronic dosing with phenylbutazone (PBZ) oxidative metabolism becomes 
more important yielding oxyphenbutazone (OPBZ) and gammahydroxyphenyl-
butazone (γΟΗΡΒΖ) as major metabolites m plasma. Both metabolites have 
pharmacological activity. Furthermore phenylbutazone and its metabol-
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ites in vitro are subject to breakdown, not only upon storage, but 
also during the procedures to determine their concentrations in biolo­
gical samples. Because of this change in metabolism and in vitro pro­
blems the interpretation of plasma concentrations is difficult, espe­
cially in relation to therapeutic and toxic effects. A new quantitative 
HPLC method was developed in which extreme care was taken to avoid de­
gradation of the compounds during the extraction procedure. With this 
method we found in 7 patients during chronic treatment concentrations 
of PBZ of Θ7 + 16 μg/ml, OPBZ of 11 + 3 μς/ιηΐ, and γΟΗΡΒΖ of 13 + 7 
цд/ті. In view of these results previously published data on plasma 
levels of phenylbutazone and its metabolites should be considered with 
reserve. A more detailed study of the pharmacokinetics of PBZ using 
this method was not possible within the context of the clinical trial. 
It was thought unethical to perform a large scale volunteers study 
because of the haematological side effects of the drug. However, 
naproxen, also an effective drug in ankylosing spondylitis, has a simi­
lar pharmacokinetic profile, be it that it has a shorter half life 
(12-15 hours) than PBZ (70 hours). Both drugs show non-linear pharma­
cokinetics with a disproportionally smaller increase of plasma levels 
with increasing dosage, in case of naproxen above 500 mg twice daily. A 
study was done on the non-linearity of the pharmacokinetics of naproxen 
in volunteers. There is a diurnal variation in the severity of com­
plaints associated with ankylosing spondylitis, and naproxen has the 
mentioned shorter half-life. Therefore also pharmacokinetic differences 
were studied between two dosage regimens: 500 bid versus 1000 once 
daily at night. Exceeding the plasma protein binding capacity upon the 
once daily dosing results in an increased distribution volume, and to a 
lesser extent an increased total body clearance. Upon twice daily 
dosing the trough serum levels are higher with a larger time span above 
a suggested effective level. The therapeutic implications of such 
findings warrant further studies in patients with rheumatic diseases. 
The usual practice in clinical trials is to collect primarily consecu­
tive data on separate efficacy parameters. Another frequently applied 
approach is the overall assessment. For an integral judgement global 
evaluations are made concerning disease activity and response to thera-
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py accomplished by comparison with pre-trial conditions or a defined 
baseline state. The reliability of an efficacy judgement would be in-
creased by adequately combining separate parameters. The main 
reason for doing this is that no single parameter can assay the overall 
disease state in ankylosing spondylitis, whereas the global assessments 
have the disadvantage of being primarily subjective impressions that 
have to be compared with one observation increasingly distant in time. 
The most important parameters in assessing the clinical disease state 
and seventy in ankylosing spondylitis are spinal pain (DSP), morning 
stiffness (MS), chest expansion (CE) and lumbar flexion index (LFI). 
This study describes the construction of an index of disease activity 
(IDA) in ankylosing spondylitis based upon these parameters. This IDA 
correlated with each of its components whereas the separate components 
between each other were only partly correlated. This justifies its use 
for studying groups of patients in a drug trial. By testing the value 
of IDA it was demonstrated that its changes (AIDA) were frequently cor-
related with the changes of the separate parameters (DSP, MS, CE, LFI) 
and, moreover, with changes in parameters (ESR, IgA) not included in 
the index and with the patient's and investigator's global judgements 
as well. This study demonstrates that combining clinically relevant pa-
rameters in a composite index can be an appropriate way to assess dis-
ease activity and for monitoring the response to treatment with NSAIDs. 
Salicylic acid derivatives - tested in only a few studies - have never 
become drugs of choice in the treatment of ankylosing spondylitis. For 
some years the new salicylic acid derivative, diflumsal, was intro-
duced with greater anti-inflammatory and analgesic potency, longer du-
ration of action and fewer side effects than its parent drug. This war-
ranted a study of the efficacy and safety of this agent in ankylosing 
spondylitis. A 12 weeks double-blind randomized drug trial, followed by 
an open extension period of 36 weeks was carried out in 38 male pa-
tients with ankylosing spondylitis. A comparison was made of diflumsal 
(500 mg bid) with phenylbutazone (200 mg bid). Both drugs were able to 
improve the seventy of symptoms and signs associated with ankylosing 
spondylitis, and this improvement was maintained throughout the 48 
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weeks study. Initially diflunisal had a more pronounced and rapid anal-
gesic action, whereas phenylbutazone was more effective in increasing 
axial mobility. Nine patients dropped out during the study: three in 
each treatment group due to side effects and one in each group due to 
inefficacy; another patient was lost to follow up. The two drugs were 
similarly safe as judged by the occurrence of clinical adverse experi-
ences, mainly gastrointestinal. This study again demonstrates the value 
of phenylbutazone in ankylosing spondylitis, but taken into account the 
possible haematological side effects, phenylbutazone would not be re-
commended as the first choice NSAID, given the availibity of several 
alternatives. The present study shows that diflunisal is capable of im-
proving the painful stiffness associated with ankylosing spondylitis in 
a dosage of 500 mg twice daily. 
In addition to the clinical parameters, progression and severity of the 
disease process in ankylosing spondylitis can be assessed by measuring 
several other variables. Serial assessments of radiological changes, 
pulmonary function and serum IgA levels are frequently used for this 
purpose. In ankylosing spondylitis the inflammation is gradually exten-
ded over the chest; besides the thoracic vertebral column and costover-
tebral joints the whole chest wall can be affected. This results in a 
reduction of the chest expansion, with possible consequences for pulmo-
nary function. However, ventilatory function is often preserved because 
of compensation by the diaphragma as the major inspiratory muscle. This 
study has shown that, although thoracic pain and chest expansion im-
proved during drug therapy, no change in vital capacity was found. It 
was therefore concluded that the vital capacity is not an appropriate 
parameter for monitoring over a limited time span the effect of treat-
ment in ankylosing spondylitis. As there is a relation between vital 
capacity reduction and the extent of radiological abnormalities, this 
reduction is not related to the actual disease activity, but mainly an 
expression of the extent of irreversible thoracic wall impairment. So 
both vital capacity and radiological features reflect merely activity 
in the past and progression over a greater time span. 
The predisposition to a flexion deformity in ankylosing spondylitis, 
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and the possibility to prevent this with various therapeutic interven-
tions, including NSAIOs, makes it important to know if an ongoing spon-
dylitis is present. Serum IgA levels have shown to be associated with 
disease activity in ankylosing spondylitis. Serial measurements of 
changes in serum IgA levels run parallel with changes in disease acti-
vity, measured by the mentioned composite index. Moreover, patients 
with extensive radiological abnormalities also had highest serum IgA 
levels. From these observations it was concluded that patients with a 
persistent elevated serum immunoglobulin A level are most at risk to 
develop extensive axial inflammation, and therefore ankylosis and a 
flexion deformity. 
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SAMENVATTING 
Spondylitis ankylopoetica is een rheumatisch ontstekingsproces, van on-
bekende oorzaak dat zich voornamelijk uit in de sacro-iliacale gewrich-
ten, wervelkolom en proximale gewrichten (heupen en schouders). De 
ziekte heeft een fluctuerend verloop en in het algemeen een gunstige 
prognose wat betreft de validiteit. De klachten van de patiënten be-
staan uit pijn en stijfheid, met name het hevigst 's nachts en in de 
ochtend. Ook tonen de patiënten een afnemende beweeglijkheid van de 
wervelkolom en borstkas. 
Daar er geen curatieve behandeling mogelijk is, hangt de behandeling 
af van een vroege diagnose en de toepassing van verscheidene therapeu-
tische maatregelen, waaronder een dagelijks actief oefenschema, fysio-
therapie en medicamenteuze behandeling met niet-steroidale anti-inflam-
matoire medicamenten (NSAIDs). Door pijn en stijfheid te verminderen 
bewerkstelligen deze medicamenten een instandhouding van een functione-
le houding en handhaving van mobiliteit. Zo kan een behandeling inder-
daad de algehele conditie van de patient verbeteren en het ontstaan van 
een flexiehouding tot een minimum beperken. De meeste patiënten zijn 
daardoor in staat tot het leiden van een redelijk normaal dagelijks 
leven en het uitoefenen van een beroep. Bij chronische rheumatische 
aandoeningen als spondylitis ankylopoetica, vormen dubbel-blinde, ge-
randomizeerde en gecontroleerde klinische trials een betrouwbare basis 
om de werkzaamheid en veiligheid van een behandeling met NSAIDs te eva-
lueren. Er zijn twee belangrijke redenen voor het verrichten van klini-
sche trials bij spondylitis ankylopoetica: ten eerste het fluctuerend 
beloop met spontane remissies en exacerbaties,en ten tweede de aard van 
de behandeling - tot nu toe symptomatisch en niet curatief. Klinische 
trials kunnen ook worden gebruikt om de waarde van bepaalde parameters 
in relatie tot ziekte-activiteit en response vast te stellen en boven-
dien andere, niet medicamenteuze aspecten van de ziekte zelf en de be-
handeling te bestuderen. 
Het doel van deze studie was het onderzoeken van de werkzaamheid en 
veiligheid van diflumsal (een salicylaat) bij spondylitis ankylopoeti-
ca, gebruik makend van phenylbutazone (een pyrazolon derivaat) als re-
ferentie behandeling. 
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In het verleden hebben verschillende vergelijkende studies de werkzaam-
heid van phenylbutazone (PBZ) bij spondylitis ankylopoè'tica aange-
toond. Bij chronisch gebruik van PBZ wordt het oxidatief metabolisme 
steeds belangrijker, waarbij oxyphenbutazone (OPBZ) en gammahydroxyphe-
nylbutazone (γΟΗΡΒΖ) als belangrijkste metabolieten in het plasma ont­
staan. Beide bezitten farmacologische activiteit. Daarnaast ontstaan 
niet alleen bij langdurig bewaren van monsters, maar ook tijdens de 
concentratie metingen, afbraakprodukten. Tengevolge van deze degrada­
tie, naast het toenemend oxidatief metabolisme, is de interpretatie van 
plasmaspiegels erg moeilijk, met name in relatie tot therapeutische en 
toxische effecten. Daarom werd een nieuwe quantitatieve HPLC-methode 
ontwikkeld, waarin uiterste zorgvuldigheid werd betracht om degradatie 
van de componenten gedurende de extractie-procedure te voorkomen. Met 
deze methode werd bij 7 patiënten tijdens chronisch gebruik van PBZ in 
het serum een concentratie van respectievelijk 87 _+ 16 μg/ιnl PBZ, 11 +_ 
3 μg/ml OPBZ en 1 3 + 7 μg/ml γΟΗΡΒΖ gevonden. Met het oog op deze re­
sultaten moeten gepubliceerde gegevens over serum concentraties van PBZ 
en zijn metabolieten met enige reserve worden geïnterpreteerd. 
Een meer gedetailleerde studie van de farmacokinetiek van PBZ, gebruik 
makend van deze methode, was met mogelijk in samenhang met de klini-
sche trial. Wegens de kans op hematologische bijwerkingen werd een 
studie bij vrijwilligers als onethisch beschouwd. Echter, naproxen, ook 
een effectief NSAID ter behandeling van spondylitis ankylopoëtica, 
heeft overeenkomstige farmacokinetische eigenschappen. Beide medicamen-
ten tonen een niet lineaire kinetiek met een achterblijvende stijging 
van plasma spiegels bij een oplopende dosering, in het geval van 
naproxen boven twee maal daags 500 mg. Deze dosis-afhankelijke farmaco-
kinetiek van naproxen werd bestudeerd bij gezonde mannelijke vrijwil-
ligers. 
De klachten bij spondylitis ankylopoëtica zijn het meest aanwezig 's 
nachts en in de ochtend; daarnaast heeft naproxen een kortere hal fwaar-
de tijd (12-15 uur) dan PBZ (70 uur). Ook dit laatste maakt bestudering 
van farmacokinetische verschillen tussen twee doseringsregimes (2x 
daags 500 mg tegenover 1x daags 1000 mg 's avonds) zinvol. Overschrei-
ding van de plasma eiwitbindingscapaciteit bij eenmaal daagse dosering 
resulteert in een uitbreiding van het verdelingsvolume, en in mindere 
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mate in een toename van de totale lichaamsklaring. Daarentegen waren 
bij de tweemaal daagse dosering de serum dalconcentraties hoger en ge-
durende een langer tijd boven een in de literatuur gesuggereerde effec-
tieve serumconcentratie. De therapeutische implicaties van deze bevin-
dingen behoeven nadere bestudering in patiënten met rheumatische aan-
doeningen. 
Gewoonlijk worden in klinische trials primair de opeenvolgende gegevens 
van de afzonderlijke parameters geregistreerd. Een andere, vaak toege-
paste, benadering is een algeheel oordeel over het bereikte resultaat 
te geven. Voor een algehele beoordeling betreffende ziekte-activiteit 
en effecten van de behandeling wordt een alles omvattende evaluatie ge-
daan door vergelijking met de periode vóór het onderzoek of met een ge-
definieerde uitgangssituatie. De betrouwbaarheid van een oordeel over 
de effectiviteit van een bepaalde behandeling zou kunnen worden ver-
groot door de aparte parameters op een adequate en zinvolle wijze te 
combineren. De voornaamste reden hiervoor is dat men met geen enkele 
afzonderlijke parameter in staat is een totaal beeld van de ziekte-
activiteit van spondylitis ankylopoëtica te geven; dit, terwijl globale 
beoordelingen het bezwaar hebben primair subjectieve indrukken weer te 
geven van waarnemingen t.a.v. één uitgangsbeoordeling die steeds verder 
in het verleden komt te liggen. De belangrijkste parameters, die de 
klinische toestand en ernst van de ziekte spondylitis ankylopoëtica 
weergeven zijn: rugpijn (DSP), ochtendstijfheid (MS), maximale ademex-
cursie (CE) en lumbale flexie index (LFI). Deze studie beschrijft de 
constructie van een samengestelde index (IDA), die de ziekte-activiteit 
weergeeft van spondylitis ankylopoëtica, gebruik makend van deze para-
meters. Deze samengestelde index correleerde met alle componenten, ter-
wijl de afzonderlijke parameters onderling slechts gedeeltelijk corre-
laties toonden. Dit rechtvaardigt het gebruik van de index bij de be-
studering van patiëntengroepen in bijvoorbeeld een geneesmiddelenonder-
zoek. Door de waarde van de index op deze manier te testen, werd ge-
vonden dat verandering hiervan (AIDA) frequent correleerde met verande-
ringen in de afzonderlijke parameters (DSP, MS, CE en LFI), en werden 
bovendien correlaties gevonden met verandering in BSE en IgA (die zelf 
geen deel uitmaakten van de index) en met het globale oordeel van pa-
tient en onderzoeker ten aanzien van ziekte-activiteit en behandelings-
effect. 
125 
Deze studie heeft aangetoond dat combineren van klinisch relevante pa-
rameters in een samengestelde index een geschikte manier kan zijn om 
ziekte-activiteit, en bovendien de effecten van een behandeling met 
NSAIDs, vast te leggen. 
Salicylaten, onderzocht in slechts enkele studies, hebben nooit een 
een grote rol gespeeld in de behandeling van spondylitis ankylopoëti-
ca. Enkele jaren geleden werd een niew salicylaat, diflunisal, geïntro-
duceerd, dat mogelijk een grotere ontstekingsremmende en pijnstillende 
werking, een langere werkingsduur en minder bijwerkingen heeft dan 
andere (acetyl-)salicylzuur derivaten. Dit rechtvaardigde een studie 
naar de werkzaamheid en veiligheid van dit medicament bij spondylitis 
ankylopoëtica. Er werd een 12 weken durend, dubbelblind gerandomizeerd 
geneesmiddelen-onderzoek gedaan, gevolgd door een 36 weken durende open 
periode bij 38 mannelijke patiënten met spondylitis ankylopoëtica. Ver-
geleken werd het gebruik van diflunisal 500 mg, tweemaal daags, met 
phenylbutazone 200 mg, tweemaal daags. Beide medicamenten waren in 
staat om de klachten en ziekteverschijnselen te verminderen, en deze 
verbetering bleef behouden gedurende het gehele onderzoek. Aanvankelijk 
bood diflunisal een wat sterker en sneller pijnstillend effect, terwijl 
phenylbutazone de axiale mobiliteit effectiever verbeterde. Negen pa-
tienten vielen uit tijdens het onderzoek: in elke behandelingsgroep 
drie wegens bijwerkingen, en één in elke groep wegens te geringe werk-
zaamheid van de behandeling; een andere patient zag af van verdere 
deelname. Beide medicamenten waren even veilig; de meest voorkomende 
bijwerkingen waren gastro-intestinale klachten. Ook in deze studie 
bleek Phenylbutazon een in principe waardevol medicament t.a.ν.behande­
ling van spondylitis ankylopoëtica, maar gelet op de mogelijke ernstige 
hematologische bijwerkingen dient dit middel geen eerste keus te zijn, 
temeer daar er verscheidene alternatieven bestaan. De huidige studie 
heeft aangetoond dat diflunisal in staat is de pijnlijke stijfheid van 
de spondylitis ankylopoëtica te verbeteren in een dosering van 500 mg, 
tweemaal daags. 
Naast de klinische parameters worden er verscheidene andere gebruikt om 
de progressie en ernst van het ziekteproces vast te stellen. Opeenvol-
gende röntgenfoto's van de wervelkolom en sacroiliacale gewrichten, 
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longfunctie-onderzoek, en serum-IgA concentraties worden hiervoor wel 
gebruikt. Bij spondylitis ankylopoetica breidt het ontstekingsproces 
zich geleidelijk over de borstkas uit; naast de thoracale wervelkolom 
en costovertebrale gewrichten kan de hele thoraxwand worden aangetast. 
De gevolgen hiervan zijn een verminderde ademexcursie, met mogelijke 
consequenties voor de longfunctie. Meestal wordt echter een goede ven-
tilatoire functie behouden wegens compensatie door het diafragma als 
voornaamste inademingsspier. Deze studie toont aan dat, ofschoon thora-
cale pijn en maximale ademexcursie verbeterden tijdens medicamenteuze 
behandeling, de vitale capaciteit in het geheel niet veranderde. Hier-
uit werd geconcludeerd dat de vitale capaciteit géén geschikte parame-
ter is voor het vaststellen van de effectiviteit van een behandeling 
gedurende een relatief korte periode als deze geneesmiddelentrial bij 
patiënten met spondylitis ankylopoetica. Daar er een relatie is tussen 
de vermindering van de vitale capaciteit en de uitgebreidheid van de 
röntgenafwij kingen, wordt de afname van de vitale capaciteit niet 
zozeer bepaald door de actuele ziekte-activiteit, maar is deze voorna-
nelijk een uiting van de uitgebreidheid van de irreversibele verande-
ringen van de thoraxwand. Zowel de vitale capaciteit als de röntgenolo-
gische afwijkingen weerspiegelen louter de ziekte-activiteit in het 
verleden annex de daardoor ontstane progressie over een langere pe-
riode. 
Vanwege de neiging tot het ontwikkelen van een flexiehouding bij spon-
dylitis ankylopoetica, en de mogelijkheid om dit te voorkomen met ver-
scheidene therapeutische maatregelen, waaronder NSAIDs, is het van 
belang te weten of er een voortschreidende spondylitis bestaat. Bij een 
actieve spondylitis ankylopoetica werden vaak verhoogde serum-IgA con-
centraties gevonden . De veranderingen daarin liepen bij opeenvolgende 
metingen parallel met de veranderingen in de ziekte-activiteit, vastge-
legd in de vermelde samengestelde index. Bovendien hadden de patiënten 
met de hoogste serum-IgA concentraties ook de meest uitgebreide rönt-
genafwijkingen. Hieruit wordt geconcludeerd, dat patiënten met een per-
sisterend verhoogd serum-IgA het meeste risico lopen om een uitgebreide 
axiale ontsteking met ankylose en flexiehouding te ontwikkelen. 
127 

CURRICULUM VITAE 
De schrijver van dit proefschriFt werd op 11 oktober 1951 te Eindhoven 
geboren. In 1970 behaalde hij aan het Sint Jorislyceum te Eindhoven het 
einddiploma HBS-b. Vanaf 1970 studeerde hij Geneeskunde aan de 
Katholieke Universiteit te Nijmegen. In 1976 behaalde hij het docto-
raalexamen en in 1978 het artsexamen. Hierna vervulde hij zijn mili-
taire dienstpicht in de Van Bredero kazerne te Vught. In september 1979 
begon hij zijn opleiding tot internist in de Universiteitskimek voor 
Inwendige Geneeskunde te Nijmegen (hoofd: destijds Prof.dr. C.L.H. 
Majoor-1-, momenteel Prof.dr. A. van 't Laar). Van maart 1982 tot eind 
augustus 1983 was hij werkzaam binnen de afdeling Rheumatologie (hoofd: 
Prof.dr. L.B.A. van de Putte) en de werkgroep Klinische Farmacologie en 
Farmacokinetiek (leiding: Prof.dr. F.W.J. Gnbnau en Prof.dr. C.A.M. 
van Ginneken) van de vakgroep Farmacologie, in welke periode het 
onderzoek werd verricht, waarvan dit proefschrift het verslag is. Op 1 
september 1984 voltooide hij zijn opleiding tot internist. Sedertdien 
ia hij werkzaam op de afdeling Rheumatologie. Hij is getrouwd met Erna 
Kokke. 
129 



STELLINGEN 
I 
Diflunisal is een bruikbaar alternatief voor de medicamenteuze behande-
ling van patiënten met een spondylitis ankylopoëtica (de Ziekte van 
Bechterew). 
dit pvoefsahrift 
II 
Het combineren van klinisch relevante ziekteparameters van een rheuma-
tische aandoening als spondylitis ankylopoëtica in een samengestelde 
index als één maat voor de ziektetoestand verdient de voorkeur boven de 
tot nu toe gangbare globale beoordelingen. 
dit -pvoefsohrift 
III 
In de context van een klinische trial bij spondylitis ankylopoëtica is 
de vitale capaciteit geen geschikte parameter om de effectiviteit van 
de behandeling vast te stellen. 
dit pvoefsohrift 
IV 
Verhoogde эегші IgA concentraties bij spondylitis ankylopoëtica wijzen 
op een actieve spondylitis en hebben mogelijk ook een prognostische be-
tekenis. 
dit proefschrift 
V 
Overschrijding van de eiwitbindingscapaciteit in het plasma bij hogere 
doses naproxen leidt niet alleen tot een toename van de klaring, maar 
minstens evenzeer tot een vergroting van het verdelingsvolume, waardoor 
hogere doses van dit middel mogelijk toch additioneel effect hebben. 
dit proefschrift 
VI 
Gebruik van 1 N HCl tijdens de extractieprocedure, als onderdeel van de 
bepaling van de concentratie, kan leiden tot een aanzienlijke degrada-
tie van fenylbutazon en zijn metabolieten. 
dit proefschrift 
VII 
De vermindering van de vitale capaciteit bij patiënten met een spondy-
litis ankylopoëtica is niet adembenemend. 
o.a. dit proefsahrift 
VIII 
De sombere verwachtingen omtrent de patiënt met een rheumatoide arthri-
tis, zoals die bij velen leven, is niet in overeenstemming met de rheu-
matologische praktijk. 
IX 
INH-profylaxe is niet alleen geboden bij bepaalde "rheuma"-patiënten, 
behandeld met prednison, maar ook bij dezelfde patiënten wanneer zij 
behandeld gaan worden met azathioprine of cyclofosfamide. 
X 
Bij een bejaarde patiënt met een invaliderende rheunatoïde arthritis, 
die een bloedingsneiging ontwikkelt, moet men ook de mogelijkheid van 
scheurbuik (vitamine C-deficiëntie) overwegen. 
AWBroekmarw ea, NTvG 1982,162:409-411 
recente eigen klinische waarneming 
XI 
Er zijn argumenten om bij de evaluatie van ziekte-activiteit van rheu-
matische aandoeningen ook de weersgesteldheid te betrekken. 
PM^ller ea, Saand J Rheum 1985,12:289-298 
XII 
Het effect van fenylbutazon op de renprestaties van paarden en de be-
schreven bijwerkingen van dit middel bij de mens bestempelen dit medi-
cament tot een paardemiddel. 
M Alvinerie, J Chromatogr 1980,181:132-134 
XIII 
Er is geen reden aan te nemen dat het wijzen op overeenkomstige trekken 
tussen malafide handelaren en kwakzalvers enig effect zal hebben, omdat 
beiden appelleren aan primair menselijke eigenschappen. 
XIV 
Het ziekenhuis "elders" mag vaak best gezien worden. 
Nijmegen, 21 juni 1985 M.J.A.M. Franssen 



